Washington University in St. Louis

Washington University Open Scholarship
All Theses and Dissertations (ETDs)
Spring 3-11-2013

A Role for Interferon Stimulated Gene-15 (ISG15) During
Chikungunya Virus Infection
Scott Werneke
Washington University in St. Louis

Follow this and additional works at: https://openscholarship.wustl.edu/etd
Part of the Immunology and Infectious Disease Commons

Recommended Citation
Werneke, Scott, "A Role for Interferon Stimulated Gene-15 (ISG15) During Chikungunya Virus Infection"
(2013). All Theses and Dissertations (ETDs). 1059.
https://openscholarship.wustl.edu/etd/1059

This Dissertation is brought to you for free and open access by Washington University Open Scholarship. It has
been accepted for inclusion in All Theses and Dissertations (ETDs) by an authorized administrator of Washington
University Open Scholarship. For more information, please contact digital@wumail.wustl.edu.

WASHINGTON UNIVERSITY IN ST. LOUIS
Division of Biology and Biomedical Sciences
Immunology

Dissertation Examination Committee:
Deborah Lenschow, Chair
Marco Colonna
Michael Diamond
Daved Fremont
Anthony French
Robyn Klein
Robert Schreiber

A Role for Interferon Stimulated Gene-15 (ISG15) During
Chikungunya Virus Infection
by
Scott William Werneke

A dissertation presented to the
Graduate School of Arts and Sciences
of Washington University in
partial fulfillment of the
requirements for the degree
of Doctor of Philosophy

May 2013
St. Louis, Missouri

TABLE OF CONTENTS
Page
iii

List of Figures and Tables
List of Abbreviations

vi

Acknowledgements

viii

Abstract

Chapter 1

Chapter 2

Chapter 3

Chapter 4

xi

Introduction

1

References

21

ISG15 is critical in the control of Chikungunya Virus infection
independent of UbE1L mediated conjugation

29

References

89

Identification of Non-Covalent binding partners for ISG15 and
potential functional consequences

96

References

138

Summary and Future Directions

142

References

173

ii

LIST OF FIGURES AND TABLES
Chapter 1
Figure 1.1

ISG15 expression during viral infection

Page
20

Chapter 2
Figure 2.1

Serum concentration of IFN and IFN-induced chemokines is
higher in CHIKV infected infants as compared to adults.

62

Figure 2.2

Higher serum IFNα in infants is not explained by differences in
viral load.

64

Figure 2.3

Neonatal mice mount a robust IFN and pro-inflammatory
cytokine/chemokine response following CHIKV infection.

66

Figure 2.4

Endogenous Type I IFN is required for the control of neonatal
CHIKV infection.

68

Figure 2.5

Adjuvant induced type I IFN production protects neonates from
CHIKV infection.

70

Figure 2.6

ISG15, independent of UbE1L, plays a critical role during the
neonatal response to CHIKV.

72

Figure 2.7

ISG15-/- and UbE1L-/- mice display similar viral loads to
WT mice.

74

Figure 2.8

ISG15-/- neonates display elevated cytokine levels during
CHIKV infection.

76

Figure S2.1

Pre-treatment with IFNβ improves the outcome of CHIKV
infection.

78

Figure S2.2

Induction of ISG15 during neonatal CHIKV infection is largely
dependent upon IFNAR1 signaling.

80

Figure S2.3

The role of ISG15 during CHIKV infection is age dependent.

82

Figure S2.4

Recombinant CHIKV viruses expressing WT ISG15 do not rescue
ISG15 -/- mice.

84

Figure S2.5

CHIKV infected ISG15-/- mice have increased ALT, AST, BUN
serum levels and decreased serum glucose levels compared to

86

iii

WT and UbE1L-/- mice.
Table S2.1

Clinical signs in adult and infant cohort.

87

Table S2.2

Splenic lymphocyte subsets in naïve WT, UbE1L-/- and
ISG15-/- neonatal mice (% total cell population, mean ± sem).

88

Figure 3.1

Mass spectrometry analysis of serum ISG15 indicates that free
ISG15 (ISG15 Hi) may be phosphorylated and the 30kDa band
(W2) is ISG15 conjugated to hemoglobin subunit beta-1.

118

Figure 3.2

Thr24 and Tyr139 were identified as potential phosphorylation
sites for serum ISG15.

120

Figure 3.3

The 30kDa ISG15 band appears to be ISG15 conjugated to
hemoglobin subunit beta-1 (preliminary data).

122

Figure 3.4

Generation of recombinant ISG15-Fc and identification of
non-covalent binding partners.

124

Figure 3.5

Human ISG15 interacts with human MDA5 by co-ip.

126

Figure 3.6

ISG15-/- cells and mice produce more IL-6 than both WT and
UbE1L-/- following pIC stimulation.

128

Figure S3.1

ISG15, independent of UbE1L, plays a critical role during the
neonatal response to certain alphavirus infections.

130

Figure S3.2

ISG15-/- and UbE1L-/- mice and cells produce less IL-6 in
response to LPS compared to WT mice/cells (preliminary data).

132

Table 3.1

Potential Non-Covalent Binding partners for free ISG15
identified via mass spec (ISG15-Fc pulldown with IFN/pIC
stimulated ISG15-/- BMM).

133

Table 3.2

Regulation of BMM cytokine production by ISG15 in response
to TLR stimulation (negative or positive regulation, free or
conjugation dependent).

137

Pretreating ISG15-/- muscle fibroblasts with recombinant ISG15

162

Chapter 3

Chapter 4
Figure 4.1

iv

results in decreased IL-6 production.
Figure 4.2

Pretreatment of WT mice with a polyclonal anti-ISG15
antibody did not impact survival, viral titers or cytokine
production during CHIKV infection.

164

Figure 4.3

Autophagy limits apoptotic induction in CHIKV infected
tissues and delays lethality of mice (Joubert et al 2012).

166

Figure 4.4

ISG15 does not appear to regulate total p62 and LC3-II levels
following autophagy induction (preliminary data).

168

Figure 4.5

CHIKV infected ISG15-/- mice may have elevated levels of
170
apoptosis at the site of infection compared to WT and UbE1L-/- mice
(preliminary data in collaboration with Pierre-Emmanuel Joubert).

Figure 4.6

Influenza B infected ISG15-/- mice have elevated cytokine and
chemokine levels compared to UbE1L-/- mice despite similar
viral loads (Deborah Lenschow).

v

172

LIST OF ABBREVIATIONS
ALT
AST
Atg
BFV
BMDC
BMM
BUN
CARD
CCHFV
CCL
CHIKV
Co-ip
CPE
CRP
CXCL
DC
DMEM
dsRNA
EAV
ECSA
Efp
γHV68
Herc5
IFN
IFNAR
IL
i.p.
IRF
ISG
ISGF
ISGylation
ISRE
kDa
LC-MS
LC3
LPS
MCP-1
MDA5
MEF
MOI
NF-κB
NK cells
NLR
Nsp

alanine aminotransferase
aspartate aminotransferase
Autophagy related gene
Barmah forest virus
Bone marrow-derived dendritic cell
Bone marrow-derived macrophages
blood urea nitrogen
Caspase activation and recruitment domain
Crimean Congo hemorrhagic fever virus
Chemokine (C-C motif) ligand
Chikungunya Virus
Co-immunoprecipitation
Cytopathic effect
C-reactive protein
Chemokine (C-X-C motif) ligand
Dendritic cell
Dulbecco’s Modified Eagle Medium
Double stranded RNA
Equine arteritis virus
Eastern, central, southern African CHIKV clade
Estrogen-responsive finger protein
Murine gama-herpesvirus 68
Hect domain and RLD 5
Interferon
Interferon α/β receptor
Interleukin
Intraperitoneally
Interferon regulatory factor
Interferon stimulated gene
Interferon stimulated gene factor
ISG15 protein conjugation
Interferon stimulated response element
Kilodalton
Liquid chromatography mass spectrometry
Microtubule associated protein 1 light chain 3
Lipopolysaccharide
Monocyte chemotactic protein 1
Melanoma differentiation associated protein-5
Murine embryonic fibroblast
Multiplicity of infection
Nuclear factor κB
Natural killer cells
NOD like receptor
non-structural protein
vi

OAS
PAMP
PBS
PCBP
PCR
PFU
pIC
PKR
PRR
PRRSV
qRT-PCR
RIG-I
RLR
RRV
s.c.
SFV
SINV
ssRNA
STAT
TLR
TNF-α
TRAF
UBA
Ubc
UbE1L
UBL
UIM
VEEV
VHS
VLP
WT
Y2H

2’-5’ oligoadenylate synthetase
Pathogen associated molecular pattern
Phosphate buffered saline
Poly(C) binding protein
Polymerase chain reaction
Plaque forming unit
Polyinosinic-polycytidylic acid
Protein kinase RNA activated
Pattern recognition receptor
Porcine reproductive and respiratory syndrome virus
Quantitative real-time PCR
Retinoic acid-inducible gene-1
RIG-I like receptor
Ross river virus
Subcutaneously
Semliki Forest virus
Sindbis virus
Single stranded RNA
Signal transducer and activator of transcription
Toll-like receptor
Tumor necrosis factor a
TNF receptor associated factor
Ubiquitin associated
Ubiquitin conjugating
Ubiquitin enzyme 1-like
Ubiquitin-like
Ubiquitin-interacting motif
Venezuelan equine encephalitis
Vps27, HRS, STAM
Virus-like particle
Wild type
Yeast 2 hybrid

vii

ACKNOWLEDGEMENTS
I would like to thank all of the members of my thesis committee, Marco Colonna, Mike
Diamond, Daved Fremont, Anthony French, Robyn Klein and Bob Schreiber for their continued
support and guidance. To be able to work with such leaders in the field of immunology has been
an incredible opportunity and has allowed me to become a better scientist. In addition, I would
also like to thank Daved Fremont and Robyn Klein for allowing me to do a rotation in their labs,
which helped me early on in my scientific career.
This thesis would not have been possible without the contribution of many different
collaborators. First and foremost, I would like to thank Clementine Schilte, Pierre-Emmanuel
Joubert and Dr. Matthew Albert from the Pasteur Institute. Our collaboration with Matthew’s lab
has resulted in two publications, both of which have contributed greatly to my thesis. I consider
both Clementine and Matthew valuable mentors and truly appreciate being able to work with
them. Visiting the Pasteur Institute is easily one of the highlights of my graduate studies and I
would like to thank Matthew for welcoming me into his lab and Clementine for showing me the
sights. I would like to thank Dr. Stephen Higgs (Kansas State University, recombinant CHIKGFP) and Dr. Michael Gale (University of Washington, FLAG-MDA5/RIGI) for contributing
reagents for my studies. Dr. Kathryn Stone (Yale MS & Proteomics) and Dr. Sophia Alvarez
(Danforth Plant Science Center) generated the mass spec data for Chapter 3. I would also like to
thank the many collaborators that we’ve had at Wash U. I have obtained reagents and advice
from many different people, including members from the following labs: Diamond (Szretter,
Brien, Pal), Klein (Daniels), Virgin (Hwang), Murphy, Fremont, and French. I would also like to
thank Suellen Greco for her help with the necropsy and blood chemistry analysis.

viii

I am indebted to my mentor, Deborah Lenschow. It’s fun to reflect on how it all started,
back at a poster session in 2007. I was drawn to Debbie’s lab from her apparent passion and
excitement for science. As my first rotation, I was given the freedom to go where the science
took me, and made a ton of mistakes. With Debbie’s guidance, I was able to bounce back and
really started to grow as a scientist. After joining the lab, Debbie challenged me to do my best
and helped me to develop my critical thinking skills. I learned early on that it was not enough to
just present data; I needed to identify my own strengths and weaknesses and to look ahead to
find the relevance of my research. Debbie was always around to discuss science, life, or how
badly the Cubs were doing that year. I admire her ability to maintain a balance in her life and
will strive for the same. I am extremely grateful for being able to learn from and work with
Debbie and would like to thank her for making my graduate experience a positive one.
Now on to the Lenschow lab, the crazy, fun, dysfunctional family that we are: Jessea
Campbell, Dave Morales, Kristen Monte, Mari Rodriguez, Anjali Rohatgi, and Jessica
Struckhoff. I really appreciate being able to walk in to a lab knowing that I can participate in a
lively discussion on science, politics, sports, sitcoms, or anything really. To be able to share our
reagents, ideas, opinions and time made for a great working environment and has definitely
contributed to my thesis. Time spent outside of the lab was just as fun. I will remember lab
lunches, Cardinals games, science conferences, the St. Louis half marathon, Cowboys & Aliens,
the Atlas Shrugged book club and a couple of epic paintball battles.
Grad school life would not be complete without the contribution of my family and
friends. I would like to thank all of my Wash U and St. Louis friends that have supported me
along the way. I am grateful for all of the adventures we’ve shared: snowboarding trips, softball
games, movies, salsa dancing, etc. Most importantly, I would like to thank my family for always

ix

being there. I am incredibly thankful for the encouragement of my parents Mark and Kathy, my
brother Brian, and all of the Taylors and the Wernekes. I couldn’t have done it without their
continuous love and support.

x

ABSTRACT OF THE DISSERTATION
A Role for Interferon Stimulated Gene-15 (ISG15) During Chikungunya Virus Infection
by
Scott William Werneke
Doctor of Philosophy in Biology and Biomedical Science
Immunology
Washington University in St. Louis, 2013
Professor Deborah J. Lenschow, Chairperson
Chikungunya fever is caused by Chikungunya virus (CHIKV), an infectious disease that
is characterized by severe joint and muscle pain in humans. The latest outbreak of CHIKV,
which began in 2005, has affected millions of people across India, Singapore, and the Indian
Ocean Island region. Type I interferon (IFN), which mediates protection against many different
viruses through the upregulation of interferon stimulated genes (ISGs), has been shown to be
essential for the control of CHIKV infection. As the role of ISGs during CHIKV infection is
largely unknown, we investigated the activity of the interferon stimulated gene ISG15.
ISG15 is a ubiquitin like molecule that has the ability to conjugate to intracellular
proteins and can also be found as a free form both intra- and extracellularly. ISG15 conjugation
has previously been shown to be essential for protection against influenza B and Sindbis virus
infections. We demonstrate that neonatal ISG15-/- mice are profoundly more susceptible to
CHIKV infection compared to WT mice. Unlike other viral models, mice lacking the ability to
form ISG15 conjugates through the deletion of the E1 enzyme UbE1L, do not display an increase
in CHIKV induced lethality. In addition, we observed no differences in viral loads between
wild type and ISG15-/- mice during the course of the infection. Instead, ISG15-/- mice displayed a
xi

dramatic increase in proinflammatory cytokines and chemokines. Our data suggests that the role
of ISG15 during CHIKV infection is conjugation independent and that ISG15 protection is
mediated not through its action as an antiviral molecule, but through regulation of the immune
response.
To identify potential mechanisms of action for unconjugated free ISG15, we
characterized both intra- and extracellular forms of ISG15 using mass spectrometry. We identify
phosphorylation as a potential post-translational modification for extracellular ISG15 and
identify the secreted 30kDa ISG15 conjugate as ISG15 bound to hemoglobin subunit beta-1. We
also identify over 140 potential non-covalent binding partners for intracellular ISG15 that are
involved in many different cellular pathways, including innate immunity, vesicular sorting, and
cell signaling. Based on our findings, we have generated preliminary data examining a role for
ISG15 in autophagy as well as a role for ISG15 in the regulation of cytokine production. Our
characterization of both intra- and extracellular ISG15 will hopefully guide future experiments
needed to determine the mechanism by which ISG15 regulates the host response to viral
infection.
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CHAPTER 1
Introduction
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Overview
In 2005, a large scale outbreak of Chikungunya Virus (CHIKV) was reported on the
Indian Ocean Island of La Reunion, where approximately 1/3 of the 770,000 inhabitants became
infected (1, 2). The scale and severity of this outbreak in combination with additional concurrent
outbreaks in India and Southeast Asia has brought this virus to the forefront of infectious disease
studies. Research on CHIKV has greatly expanded in an attempt to understand both the viral life
cycle as well as the host response to infection. Critical to the control of CHIKV infection is the
induction of type I interferons (IFN) (3-5). Interferons, named for their ability to “interfere” with
viral replication, act by generating an antiviral state within host cells (6-8). Type I IFN mediates
protection through the upregulation of hundreds of interferon stimulated genes (ISGs), although
how ISGs provide protection is not well understood. In our introduction, we give an overview of
our current knowledge of CHIKV, the type I IFN response, as well as the interferon stimulated
gene ISG15.
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Chikungunya Virus
History of CHIKV outbreaks (Epidemiology)
Chikungunya virus (CHIKV) was originally isolated in Tanzania in 1952 (9). Since then,
CHIKV has been documented to be responsible for numerous outbreaks across Africa and
Southeast Asia. Repeated isolated outbreaks of CHIKV have been reported in southern, eastern,
and western Africa between the 1960s-1990. In the 1960s, CHIKV was reported in Asia, causing
major outbreaks in Myanmar, Thailand, Sri Lanka and India (10). Sporadic outbreaks were also
reported in Thailand, Indonesia and the Philippines in the 1980s and Malaysia in the 1990s (11).
Phylogenic analysis suggests that CHIKV originated in Africa and subsequently spread to Asia.
Currently there are three evolutionary clades of CHIKV, including West African strains, Eastern,
Central and Southern African strains (ECSA) and a third clade from Asia (12).
The most recent large scale outbreak of CHIKV began in Kenya in 2004, spreading to the
Comoros and eventually appearing on La Reunion Island in March of 2005 (13, 14). The peak of
the La Reunion outbreak occurred in December 2005-April 2006, where 38% of the population
became infected and 237 deaths were attributed to CHIKV infection (15). The epidemic soon
spread to surrounding islands, including Comoros, Mayotte, Mauritius and Madagascar. An
estimated 1.6 - 6 million cases were reported in India from 2006-2007 (16-18). The epidemic
also affected areas of Southeast Asia, with outbreaks in Thailand, Singapore and Indonesia.
Phylogenic studies have confirmed that the ECSA clade was responsible for the 2005-2009
epidemic (1, 2).
Imported cases of CHIKV from travelers returning from these areas to the U.S., Europe,
and other countries fueled fears of large outbreaks in previously unexposed urban populations.
Increased global communication and travel may make it possible for easier spread of the virus,
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which was exemplified by a small outbreak (250 cases) in Italy in 2007 and in Southern France
in 2010 (19-21). As a result, research on CHIKV has greatly increased over the last ten years in
an attempt to gain a better understanding of CHIKV pathogenesis (11).

Transmission and Viral Vectors
CHIKV is an arbovirus, a virus that is transmitted by arthropod vectors. CHIKV is
transmitted to humans primarily by mosquitoes. There are two distinct transmission cycles for
CHIKV: (1) sylvatic and (2) human-mosquito-human. Sylvatic transmission is confined to
Africa, where outbreaks normally affect smaller populations and are dependent on forestdwelling Aedes mosquito species, including Aedes furcifer, Aedes taylori, Aedes luteocephalus,
Aedes africanus, and Aedes neoafricanus. Monkeys, birds, rodents and other vertebrate species
serve as reservoirs for CHIKV outside of epidemic periods (11). The absence of sylvatic
transmission in Asia provides additional evidence that CHIKV originated in Africa before being
introduced in Asia.
Non-sylvatic transmission, human-mosquito-human transmission, is dependent on
mosquitoes that live in urban areas with a close association with humans. In Asia, Aedes Aegypti
has been described as a predominant vector for CHIKV. However, a new mosquito vector has
been described following the La Reunion outbreak: Aedes Albopictus. CHIKV La-Reunion
shows only 1-2% amino acid changes when compared to the Tanzania CHIKV reference strain
(3). The impact of these mutations on the pathogenicity of the La-Reunion CHIKV strain is not
well understood, however research has shown that a mutation in the E1 protein of CHIKV is in
part responsible for the use of Aedes Albopictus as a new viral vector (22). It is postulated that
the alanine to valine amino acid change at position 226 in the E1 CHIK protein allows for
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decreased dependency on cholesterol for CHIKV growth, allowing for adaptation in Aedes
Albopictus. Additional mutations found in the E2 La Reunion envelope protein, E2- G60D and
E2- I211T, are thought to maximize the effectiveness of the E1 A226V mutation for Ae
Albopictus infectivity (23).
Aedes Albopictus as a new mosquito vector adds to concerns of increased global
outbreaks for CHIKV due to wide distribution of this vector in urban and Western populations.
Aedes Albopictus is found in temperate regions where Aedes Aegypti is scarce, including parts of
the U.S., Europe, China and Japan (11). Ae. Albopictus has the ability to colonize various
ecosystems and may be a difficult vector to control.

Symptoms (Acute and Long Term)
Chikungunya in Makonde language translates to “that which bends up,” which refers to
stooped posture developed during infection resulting from severe muscle and joint pain (11).
More than 95% of CHIKV infected adults are symptomatic (24). Patients that are infected with
CHIKV suffer from polyarthralgia, myalgia, asthenia, fever, headache, and rash. Symptoms may
also include acute tenosynovitis and gastrointestinal complaints (1, 11). Acute symptoms usually
persist for 1-10 days. During the outbreak on La-Reunion, novel disease symptoms were also
described that had previously not been reported for CHIKV, including respiratory or kidney
failure, lymphopenia, lethal hepatitis and encephalopathy (25). In addition, although CHIKV can
normally be resolved by healthy individuals, La-Reunion reported approximately 250 deaths,
seen in infants and elderly (26). Several animal models have been developed that mimic the
symptoms observed during CHIKV infection in humans (27-30).
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Chronic arthralgia can persist weeks, months, or even years after initial infection.
Symptoms usually include fluctuating joint pain that does not change in anatomical location.
Virus is usually not detected in circulation after 2 weeks by RT-PCR, although IgM specific
responses can persist years after infection. Chronic symptoms normally correlate with age, viral
load and CRP (C-reactive protein) levels observed during acute infection (31). It remains unclear
whether chronic symptoms result from poor regeneration of joint tissue following damage during
acute infection, autoimmune disease induced during infection, or whether the virus is able to
persist at low levels in select tissues (30).

CHIKV classification
Chikungunya virus belongs to the Alphavirus genus and is a member of the Togaviridae
family. The alphavirus genus can be further subdivided in to 7 antigenic complexes based on
serological cross reactivity: Barmah Forest (BF), Eastern equine encephalitis (EEE), Middelburg
(MID), Ndumu (NDU), Semliki Forest (SF), Venezuelan equine encephalitis (VEE), and
Western equine encephalitis (WEE) (32). CHIKV belongs to the Semliki Forest Complex.
Alphaviruses were also once classified by their geographic prevalence in to Old World and New
World Viruses. Old world alphaviruses are mostly arthrogenic and include Chikungunya virus,
O’Nyong Nyong Virus (ONNV), Semliki Forest (SFV), Sindbis virus (SIN) and Ross River
(RRV). In contrast, new world alphaviruses cause encephalitis and include Venezuelan, Eastern
and Western Equine Encephalitis viruses (33).

CHIKV genome and replication
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Chikungunya, like all alphaviruses, is an enveloped positive sense, single stranded RNA
virus. Electron microscopy indicates that CHIKV is about 70nm in diameter (34). General steps
regarding the replication cycle for CHIKV is largely deduced from data obtained from other
Alphaviruses and is supported by the sequence similarities that are conserved in CHIKV (32).
The genome is enclosed by capsid proteins (C) that form a nucleocapsid, which is
enveloped in a host-derived lipid bilayer that contains two viral envelope glycoproteins E1 and
E2. These envelope proteins are necessary for receptor binding (E2) and membrane fusion (E1)
of host cells. The receptor for CHIKV is unknown, and is likely responsible for restricting the
tropism of CHIKV. The primary targets of CHIKV infection are thought to be fibroblasts, found
in the muscle and connective tissue (4). Epithelial (HeLa, 293T, Vero) and endothelial
(TrHBMEC) cell lines also support CHIKV growth (3). Unlike RRV or VEEV, most
hematopoietic cells do not support CHIKV growth, although replication can be seen in primary
monocytes and macrophages (3, 30, 35). After receptor binding, virions are endocytosed and the
nucleocapsid is released into the cytosol following pH mediated conformational changes in the
E1-E2 dimer that allows for fusion (36-38).
Once the nucleocapsid has disassembled, translation of the viral genome and replication
occurs. The CHIKV genome is approximately 11.8-kb long and is organized as follows: 5’ capnsP1-nsP2-nsP3-nsP4-(junction region)-C-E3-E2-6k-E1-poly(A)-3’ (32). The four non-structural
proteins (nsP1-4) are translated directly from the viral genome to form polyprotein P1234 and
P123 precursors. These polyproteins are processed by an internal viral protease, located within
nonstructural protein nsP2. The nonstructural proteins are responsible for generation of a
complementary minus strand RNA, plus strand RNA and subgenomic RNA. The subgenomic
RNA is derived from the minus strand RNA and is used to generate the structural proteins E1,
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pE2, Capsid and 6k (a small peptide that may act as a signal sequence for the translocation of
E1). pE2 is eventually cleaved to generate E2, which forms a heterodimer with E1, and E3,
which is not incorporated into the virion. The function of E3 is unknown, although may share
similarities with SINV E3, which is thought to be involved in proper folding of viral envelope
glycoprotein spike formation (32).
Following genome replication and viral protein production, virion assembly occurs via
nucleocapsid formation in the cytoplasm. Alphavirus capsid proteins contain RNA binding
domains that allow for incorporation of the genome into the nucleocapsid. The capsid proteins
oligomerize to form an icosahedral shell which then diffuses freely through the cytoplasm to
reach the plasma membrane. At the cell membrane, the nucleocapsid obtains a lipid bilayer
composed of mature envelope glycoprotein spikes that are composed of trimers of E1-E2
heterodimers. The E2 protein is necessary for interaction with the capsid proteins, leading to
maturation of the nucleocapsid which then allows for budding (32).

Pathogen recognition and interferon production
In humans, viremia for CHIKV infection peaks by day 2 p.i., sharply declines during
days 3 and 4 p.i. and is undetectable by day 5 (39). This quick decline of viremia suggests that
the innate immune response is critical for the early response to CHIKV infection. As a result,
current research on CHIKV has focused on understanding the type I interferon response to
infection. Here, we review the type I interferon signaling pathway and its importance in
controlling CHIKV infection.

Pattern Recognition Receptors and RNA Virus Detection
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Production of type I IFN is dependent on the ability to detect invading pathogens through
the use of pattern recognition receptors (PRRs). PRR recognize conserved pathogen structures
known as pathogen-associated molecular patterns (PAMPs). Toll-like Receptors (TLRs), NOD
like receptors (NLRs), and RIG-I-like receptors (RLRs) are well described PRRs that play a role
in pathogen detection. Although the signaling components for each PRR can vary, each pathway
ultimately leads to the activation of NF-κB and/or IRF3, which are necessary for IFN
transcription (40).
TLRs contain a luecine-rich repeat (LRR) for detection of PAMPs, a transmembrane
domain and an intracellular Toll/IL-1 receptor (TIR) domain that mediates downstream
signaling. TLRs are localized to either the plasma membrane or endosomal compartment and
respond to bacterial and/or viral components. The primary TLRs responsible for RNA virus
detection are TLR3 (dsRNA) and TLR7/8 (ssRNA rich in G/U residues) and are localized to the
endosome. Phagocytosis of nucleic acids from apoptotic or necrotic cells triggers TLR signaling,
which leads to macrophage or dendritic cell activation. Downstream signaling of TLR3 and
TLR7/8 is mediated by TRIF and MyD88, respectively, which leads to the production of IFN
and other pro-inflammatory cytokines (40, 41).
The two best described RLRs, RIG-I (retinoic acid-inducible gene I) and MDA5
(melanoma differentiation-associated gene 5), are both cytosolic RNA sensors that are
responsible for detecting intracellular RNA viruses. RIG-I and MDA5 contain a C-terminal
DExD/H box RNA helicase domain for viral RNA recognition and N-terminal caspaserecruitment and activation domain (CARDs) which mediate downstream signaling (42). RIG-I
recognizes dsRNA with 5’ triphosphate and MDA5 recognizes long dsRNA. Engagement of
RIG-I or MDA5 allows for the association with Cardif /IPS-1/MAVS/VISA, which leads to the
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activation of NF-B (nuclear factor κB), AP-1 (a heterodimer of activating transcription factor 2
(ATF2) with c-Jun), IRF7 and IRF3 (7, 42).
NLRs are cytosolic sensors that detect a wide array of PAMPs and other physiological
stressors and are primarily characterized by their ability to activate the inflammasome. The role
for NLRs in RNA virus detection is less defined, although recent literature suggests that the NLR
NOD2 plays a role in the detection of Respiratory Syncytial, Influenza A and Parainfluenza
viruses (43). NLRX1 has also been shown to regulate IFN production (44). Both NOD2 and
NLRX1 interact with Cardif, resulting in a similar downstream signaling cascade as RLRs.
Translocation of NF-B, AP-1 and IRF3/7 to the nucleus allows for type I IFN production (40,
42).

Interferons
There are three classes of IFN: type I, II and III. Type II IFN consists of a single member,
IFNγ which signals through the IFNγ receptor complex (IFNGR) and mediates broad immune
responses to pathogens. Type III IFNs consist of IFNlambda1-3 and signal through a receptor
complex composed of IFNLR1 (IL-28α) and IL-10R2 (IL-10Rβ). The activity of type III IFNs is
less well known, however it has been proposed that type III IFNs behave similar to type I IFNs.
Type I IFNs are well characterized and are the focus of this section. (45, 46).
Type I IFNs are made up of seven classes: IFN, IFN, IFN, IFN, IFN, IFN, and
IFN, with IFN and IFN being the focus of antiviral studies. Although there is only one
subtype for IFN, there are several subtypes of IFN (13 in humans, at least 10 in mice). Type I
IFNs are regulated at the transcriptional level, following PRR activation. The promoter regions
of IFNβ and IFNα contain regulatory cis elements called positive regulatory domains (PRDs).
10

The IFNβ promoter contains 4 PRD domains I-IV, whereas IFNα contains PRDI and PRDIII-like
elements (PRD-LE). PRDI and III are the binding sites for the IRF family members, whereas
PRDII and PRDIV bind to NF-κB and AP-1, respectively. Binding of transcription factors to the
promoter region forms an “enhanceosome,” which allows for nucleosome displacement and
recruitment of the transcription complex TFIID for gene expression. (42)
After virus has been detected by an infected cell, type I IFN is released, acting in an
autocrine and paracrine fashion on both infected and uninfected cells. All type I IFNs mediate
there antiviral activity by binding to a common IFN/ receptor (IFNAR), a complex between
IFNAR1 and IFNAR2. IFNAR1 and IFNAR2 associate with intracellular Janus activated kinases
(JAKs) tyrosine kinase 2 (Tyk2) and JAK1 respectively. Tyk2 and JAK1 are transphosphorylated following IFNAR oligomerization. Activation of Tyk2 and JAK1 allows for
phosphorylation of STAT1 and STAT2 (signal transducer and activator of transcription).
Phosphorylation of STAT1 and STAT2 allows for dimerization followed by association with
IRF9. This complex is known as interferon-stimulated response factor 3 (ISGF3). ISGF3
translocates to the nucleus and activates the transcription of interferon stimulated genes (ISGs)
by binding to interferon stimulated response elements (ISRE). Hundreds of ISGs are transcribed
in response to type I interferon signaling although the antiviral function for many of these genes
remains unknown. (46)

A role for type I IFN during CHIKV infection
Research on CHIKV has demonstrated that interferons play an essential role during viral
infection. Pretreatment of the human epithelial Hela cell line with type I or type II interferon
inhibits viral replication and viral induced CPE (3). Adult C57Bl/6 mice are resistant to CHIKV
infection whereas IFNAR-/- mice die by day 3 p.i. and show wide viral dissemination and high
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viral titers (4). IFNAR-/- mice also show high serum levels of IFN and IFN on day2 p.i., which
indicates that IFN is induced during CHIKV infection. Wild type mice infected with CHIKV do
not show systemic production of IFN/, however it’s thought that local production of type I
IFN is sufficient to protect wild type mice and limit viral dissemination. Sera from CHIKV
infected human patients also have elevated type I interferon levels (5). Type II interferon
production does not appear to be as critical in controlling CHIKV infection, as IFN levels are
not elevated in the sera of human patients and IFN-/- mice survive CHIKV infection (5).
In order to understand how type I interferon protects against CHIKV infection,
mechanistic studies have been done to describe the cell types necessary to produce and respond
to type I IFN. Surprisingly, immature and mature monocyte-derived cDCs, isolated pDCs and
monocytes are unable to produce type I IFN in response to CHIKV treatment. Instead, robust
production of IFN can be detected from primary human foreskin fibroblasts and MRC-5 cells
following CHIKV infection. This data suggests that hematopoietic cells do not produce type I
IFN following direct stimulation with CHIKV and that fibroblasts may be responsible for the
initial production of type I IFN. Bone marrow chimera studies have shown that type I IFNs act
on non-hematopoietic cells in order to control CHIKV infection. In addition, search for viral
sensors for CHIKV has revealed that both Cardif and MyD88 signaling pathways contribute to
the control of CHIKV. In terms of the ISGs that mediate these antiviral activities against
CHIKV, little is known. To start to address the mechanism by which type I IFNs mediate control
of CHIKV infection, we turned our attention to the interferon stimulated gene ISG15. (5)

Interferon Stimulated Genes
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Signaling through the IFNAR receptor leads to the induction of over 300 interferon
stimulated genes (ISGs) (47). Many of the proteins that are induced by IFN play a role in
pathogen recognition (PRRs) and act as transcription factors that amplify IFN production.
Additional ISGs also have direct antiviral function. The effector activities of antiviral ISGs
include a wide variety of functions, including but not limited to cytoskeletal remodeling,
apoptosis induction, RNA regulation (splicing, editing, and degradation), and other posttranslational modifications (45).
Some of the best known antiviral effectors include Mx GTPases, PKR, OAS and
RNaseL, as well as ISG15. MxA monomers bind to viral nucleocapsid proteins, which leads to
their degradation and limits viral replication. 2’, 5’ –oligoadenylate synthetase 1 (OAS1) is
activated by viral dsRNA to generate 2’,5’ oligadenylates that subsequently bind to and activate
RNaseL, which cleaves cellular and viral RNAs. PKR phosphorylates eukaryotic translation
factor 2α (EIF2α) after binding to viral RNAs, which results in translation inhibition. Additional
ISGs include the translation regulators IFIT1 and IFIT2 (IFN-induced protein with
tetratricopeptide repeats), Viperin, APOBEC (apolipoprotein B mRNA-editing enzyme, catalytic
polypeptide), ISG20, and members of the tripartite-motif containing (TRIM) proteins such as
TRIM1. Below, we discuss in greater detail the activity of ubiquitin like molecule ISG15. (45)

ISG15
One of the most predominant genes induced by type I IFN is ISG15 (47, 48). ISG15 is a
17kDa molecule that contains two ubiquitin-like domains connected by a peptide linker. Both
domains of ISG15 contain approximately 30% identity to ubiquitin and assume a β-grasp fold
secondary structure that is almost identical to that for ubiquitin (49). ISG15 is generated as a
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propeptide that is processed by an unidentified cellular protease (possibly Ubp1) to reveal a
conserved C-terminal LRLRGG diglycine motif that allows for ISG15 to be conjugated to target
proteins (50, 51). Due to ISG15s structural similarity to ubiquitin, we will briefly review the
activity of the ubiquitin family and ubiquitin like proteins (UBLs).

Ubiquitin and UBLs
Ubiquitin is a 7kDa protein that forms isopeptide bonds with lysines of target proteins
through a conserved LRLRGG C-terminal motif. Post-translational modification of proteins by
ubiquitin can lead to a variety of functional consequences, dependent on the specific type or
ubiquitin modification. The most commonly known function of ubiquitin is to target intracellular
proteins to the proteasome through the formation of Lys48 poly-ubiquitin chains, which leads to
protein degradation. Ubiquitin can also play an important role in many other cellular processes,
including apoptosis, endocytosis, histone regulation and viral budding. (52, 53)
Ubiquitin like proteins (UBLs) share the same structural fold as ubiquitin and can also be
conjugated to target proteins. Commonly known UBLs include SUMO-1 (small-ubiquitin-related
modifier), Nedd8 (also known as RUB1 (related-to-ubiqutin-1)), Fat10, and several members of
the autophagy pathway (Atg8, Atg12). Sumoylation (conjugation of proteins to SUMO-1) allows
for protein localization around the nucleus and can also compete for ubiquitin binding sites to
prevent ubiquitin mediated degradation. Nedd8 modifies subunits of the SCF (Skp1/cullin-1/Fbox protein) ubiquitin ligase family and is required for maximal ligase activity. Fat10 is also
thought to compete for ubiquitin binding sites. Unlike ubiquitin, UBLs are not known to selfconjugate, therefore act as monomeric conjugates. (54, 55)
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Conjugation to target proteins for both ubiquitin and UBLs is mediated through an
E1/E2/E3 enzymatic cascade. The C-terminus of the Ubl is activated via adenylation, allowing
for the formation of a thioester bond with the Ubl activating enzyme E1. The ubiquitin like
molecule is then transferred to a cysteine side chain of the conjugating enzyme E2, which can
also bind to an E3 ligase protein. The E3 protein associates with the acceptor protein and allows
for transfer of the ubiquitin moiety to the target protein. Modification of ubiquitin or UBLs to
target proteins is reversible, as there exists several De-ubiquitinating and related enzymes. (55)

The ISG15 conjugation cascade
Similar to ubiquitin, ISG15 modification (ISGylation) of target proteins requires an E1,
E2, E3 enzymatic cascade. UBE1L is thought to be the major E1 activating enzyme for ISG15,
which is specific for ISG15 conjugation (56). The ubiquitin E2 protein UbcH8 appears to be the
major E2 for ISG15 (57, 58). Herc5 is thought to be the most important E3 protein for
ISGylation (59-61), although other additional E3s have been identified (e.g. Rsp5p, Efp) (57,
62). In addition, ISG15 can be removed from targeted proteins by the deconjugating enzyme
UBP43 (63). Unlike ubiquitin, ISG15 is not constitutively expressed. All members of the ISG15
cascade, including UBP43, are induced following type I IFN stimulation.

A role for ISG15 during viral infection
The early induction and high levels of expression of ISG15 following IFN stimulation
has led to the investigation into ISG15 as an antiviral molecule (Fig 1.1). Neonatal mice infected
with the alphavirus Sindbis virus show >100 fold increase in ISG15 RNA as well as robust
ISG15 conjugate formation (64-66). The first demonstration that ISG15 could function as an
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antiviral molecule was overexpression of ISG15 through the use of a recombinant Sindbis virus
construct. It protected IFNAR-/- mice from Sindbis infection (66). Subsequent studies showed
that ISG15-/- mice were more susceptible to Sindbis virus (67). ISG15s role as an antiviral
molecule is not limited to Sindbis infection, as ISG15-/- mice are also susceptible to herpes
simplex virus, gamma herpes virus, and influenza A and B viruses (67).
The ability of ISG15 to form conjugates appears to be critical for its antiviral role during
Sindbis virus infection. UBE1L-/- mice, which lack the ability to form ISG15 conjugates (68),
have similar lethality as ISG15-/- mice to Sindbis infection (69). ISG15-/- mice infected with a
recombinant Sindbis virus that expresses an unconjugatable form of ISG15 (LRLRAA) are not
protected from viral induced lethality while the expression of wild type ISG15 (LRLRGG)
protects ISG15-/- mice (67, 69). The importance of ISG15 conjugation has also been
demonstrated for other viral infections. UBE1L-/- mice infected with influenza B phenocopy
ISG15-/- mice, with similar lethality and lung viral titers (70). Further support for the importance
of conjugation comes from the immune evasion strategies employed by viruses. The NS1 protein
of influenza B has been shown to directly inhibit ISG15 conjugate formation (56). OTU-domain
containing viral proteins, such as the L protein of Crimean-Congo hemorrhagic fever virus
(CCHFV) or the Nsp2 protein of Equine Arteritis virus (EAV), also reduce the level of ISG15
conjugates (71). The ability of viruses to target ISGylation suggests that this is an important
immune evasion strategy.

ISG15 Function
Although ISG15 has been shown to be an important antiviral molecule, the mechanism
by which ISG15 inhibits viral infection is not well understood. Due to the apparent similarities
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between ISG15 and ubiquitin as well as the demonstrated importance of ISG15 conjugation in
vivo, current research has focused on determining the functional consequence of ISG15
modification of target proteins. Over 200 potential targets of ISGylation have been identified
using mass spectrometry. Targets of ISGylation take part in a number of cellular processes,
including cell cycle, cell metabolism, and immune signaling pathways (72, 73). Viral proteins
have also been shown to be targets of ISGylation (74, 75). A potential mechanism by which
ISG15 targets such wide array of proteins with only one main E3 has been suggested. Herc5 has
been shown to associate with polyribosmes, allowing for modification newly synthesized
proteins (75). However, ISG15 modification appears to be specific, as not all newly translated
proteins are ISGylated.
ISG15 modification of target proteins has been suggested to cause either a loss or gain of
function for the targeted protein. ISGylation of Ubc13 causes a reduction in polyubiquitinated
TRAF6, which consequently leads to a decrease in NF-B activation (76). In addition, ISG15
modification of filamin B disrupts its scaffold function which then downregulates the type I
interferon-induced JNK signaling pathway (77). Conjugation of ISG15 to RIG-I has also been
suggested to negatively regulate RIG-I mediated IFN induction (78). So far, modification of
4EHP is the only reported gain of function for ISG15 (79). ISGylation of 4EHP enhances its capbinding activity which allows for inhibition of mRNA translation. Unlike ubiquitin, ISGylation
has not been shown to directly lead to degradation of target proteins (80).
Much less work has gone into studying the importance of free ISG15 during viral
infection. In vitro studies have demonstrated that expression of ISG15 interferes with budding of
HIV-1 and Ebola virus like particles, although it remains unclear if this is conjugation
independent (79, 81-83). Free ISG15 has also been shown to be released extracellularly and has
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been suggested to have cytokine like activity. Non-conjugated ISG15 can be detected in the sera
of humans treated with IFN as well as mice infected with certain viruses. PBMCs and nonhematopoietic cell lines secrete ISG15 in response to IFN (84). Recombinant ISG15 has been
shown to increase NK cell proliferation and lytic activity (85). Extracellular ISG15 has been
shown to act as a neutrophil chemoattractant and can upregulate e-cadherin expression on
dendritic cells (86, 87). Most recently, recombinant ISG15 in concert with IL-12 stimulation has
been shown to upregulate IFNγ (88). Although ISG15 appears to have cytokine activity, a
receptor for ISG15 has not been identified.
Data that we have generated indicates that ISG15 is expressed following CHIKV
infection. Nine day old wild type neonates were infected with CHIKV and ISG15 induction was
assessed by qRT-PCR and western blot analysis. ISG15 mRNA at the site of infection is detected
as early as 3hrs p.i. with peak levels obtained after 24hrs. Lung, liver and serum from nine day
old wild type neonates show robust ISG15 induction and ISG15 conjugate formation by western
blot analysis. The documented role for ISG15 in the host response to viral infection, including
Sindbis virus infection, prompted us to evaluate its action in CHIKV pathogenesis.
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Figure 1.1 Forms of ISG15 expression during viral infection. Detection of viral infection
leads to upregulation of type I IFN, which mediates its activity through the induction of
interferon stimulated genes (ISGs). The ubiquitin-like molecule ISG15, shown to play an
important role during several viral infections, is upregulated along with members of the ISG15
conjugation cascade: UbE1L (E1), Ubc8 (E2) and Herc5 (E3). This allows ISG15 to be
conjugated to many different intracellular proteins. In addition, ISG15 can be found as a free
form, both intra- and extracellularly. It is thought that extracellular ISG15 may have cytokine
like activity via binding to an unidentified cell surface receptor. Figure generated by Nadia
Giannakopoulos.
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Figure 1.1
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CHAPTER 2
ISG15 is critical in the control of Chikungunya Virus infection
independent of UbE1L mediated conjugation

This chapter contains data published in the following publication with significant contribution
from Clementine Schilte.
Werneke SW, Schilte C, Rohatgi A, Monte KJ, Michault A, et al. (2011) ISG15 is critical in the
control of Chikungunya virus infection independent of UbE1L mediated conjugation. PLoS
Pathog 7: e1002322.
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Abstract
Chikungunya virus (CHIKV) is a re-emerging alphavirus that has caused significant disease in
the Indian Ocean region since 2005. During this outbreak, in addition to fever, rash and arthritis,
severe cases of CHIKV infection have been observed in infants. Challenging the notion that the
innate immune response in infants is immature or defective, we demonstrate that both human
infants and neonatal mice generate a robust type I interferon (IFN) response during CHIKV
infection that contributes to, but is insufficient for, the complete control of infection. To
characterize the mechanism by which type I IFNs control CHIKV infection, we evaluated the
role of ISG15 and defined it as a central player in the host response, as neonatal mice lacking
ISG15 were profoundly susceptible to CHIKV infection. Surprisingly, UbE1L-/- mice, which
lack the ISG15 E1 enzyme and therefore are unable to form ISG15 conjugates, displayed no
increase in lethality following CHIKV infection, thus pointing to a non-classical role for ISG15.
No differences in viral loads were observed between wild-type (WT) and ISG15-/- mice,
however, a dramatic increase in proinflammatory cytokines and chemokines was observed in
ISG15-/- mice, suggesting that the innate immune response to CHIKV contributes to their
lethality. This study provides new insight into the control of CHIKV infection, and establishes a
new model for how ISG15 functions as an immunomodulatory molecule in the blunting of
potentially pathologic levels of innate effector molecules during the host response to viral
infection.
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Introduction
Chikungunya virus (CHIKV) is a member of the genus Alphavirus, which are enveloped
positive-strand RNA viruses transmitted by mosquitoes. It was first isolated in Tanzania in 1952,
and reported to cause severe fever as well as myalgias, joint pain and rash within 2-5 days of
infection (1, 2). Recently, CHIKV reemerged in Eastern Africa and has developed into a major
epidemic in the Indian Ocean region. In 2006, an outbreak on the island of La Réunion resulted
in the infection of approximately one-third of the inhabitants (3, 4). It has since spread to India
and Southeast Asia with estimates of between 1-6 million people having been infected (5, 6).
Concerns for the globalization of this virus has evolved given the continuation of this epidemic,
the high serum viremia seen in infected patients, and mutations in the currently circulating strain
of CHIKV that have allowed it to adapt to a more widely distributed mosquito vector (7). These
concerns have been raised by both an increase in the number of foreign travelers contracting
CHIKV and returning to both Europe and the United States, and by the possibility of spread by
infected individuals, the latter being exemplified by the outbreak in Italy in 2007 and in Southern
France in 2010 (5, 8, 9).

The typical clinical presentation of adults infected with CHIKV includes fever, rash,
arthralgias and severe myalgias. Infected neonates, however, display more severe disease, with
symptoms including encephalopathy and cerebral hemorrhage, with a subset of these infants
developing permanent disabilities (10). During the recent epidemic, it was reported for the first
time that CHIKV-infected mothers can transmit the virus to their newborns during delivery, with
a vertical transmission rate of approximately 50%, and in some instances infection resulted in
mortality (10). This age dependence of disease severity has also been reported for other
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alphaviruses and can be reproduced in mouse models through the infection of suckling mice.
Indeed, it has been shown that neonatal mice succumb to Ross River Virus (RRV) (11), Semliki
Forest Virus (SFV) (12), Sindbis Virus (SINV) as well as CHIKV (13-15). There are likely
several factors that contribute to this increased sensitivity in neonates, including alterations in the
neonatal immune response.

Regarding immune function in neonates, developmental delays have been described for
the adaptive immune responses, however less is known about neonatal innate responses. While
still controversial, many reports indicate that neonatal responses are diminished as compared to
adults. For example, cord blood cells stimulated with TLR ligands produced low levels of TNFα,
IL-1β, and IL-12 (16). Neonatal plasmacytoid DCs have also been shown to have impaired
production of type I IFN in response to CpG stimulation (17). It has been shown that LPS does
not effectively activate IRF-3 dependent responses, including the production of IFNβ (18). The
response to cytokines may also be impaired as there is evidence that STAT-1 recruitment
following IFNγ stimulation is less efficient in neonatal than in adult leukocytes (19). Based on
the critical role of type I IFN in the control of CHIKV infection (20), we considered the
possibility that neonates may have a developmental delay in their type I interferon response,
possibly contributing to their increased susceptibility to CHIKV infection and viral
dissemination.
In response to CHIKV infection, the production of type I IFNs is triggered by the
engagement of the RLR pathway (20, 21). IFNs then stimulate the induction of hundreds of
interferon stimulated genes (ISGs) and it is through these ISGs that IFNs mediate their effector
function (22). One of the earliest ISGs induced following IFN stimulation is ISG15. ISG15 is a
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17kDa protein that contains two ubiquitin-like domains connected by a proline peptide linker
(23). Similar to ubiquitin, ISG15 can form conjugates with an array of intracellular host and viral
proteins through the use of an E1 (UBE1L), E2 (UbcH8), and E3 (e.g., Herc5, Efp, HHARI)
enzymatic cascade (24-28). Conjugation of ISG15 to target proteins has been suggested to cause
either a gain or loss of function of the targeted protein, although the consequences of ISG15
conjugate formation are not well understood (29-32). An unconjugated form of ISG15 can also
be found in the sera of humans treated with IFN-βser as well as in virally infected mice (33, 34).
The released form of ISG15 has been suggested to have cytokine like activity (35-37), however
its role during an antiviral immune response has not been examined.

The rapid induction of ISG15 following IFN stimulation has led to the identification of an
antiviral role for ISG15 during infection. ISG15-/- mice display increased susceptibility to SINV,
herpes simplex virus-1 (HSV-1), gamma herpes virus (γHV68), influenza A and B viruses, and
vaccinia virus (34, 38). ISG15-/- mice infected with influenza B virus display a 2-3 log increase
in lung viral titers as well as elevated cytokine and chemokine levels (34). The ability of ISG15
to conjugate to target proteins appears to be essential for ISG15’s antiviral activity during certain
viral infections, as UbE1L-/- mice, which lack the ability to form ISG15 conjugates, phenocopy
ISG15-/- mice during both SINV and influenza B virus infection (39-41). Further support for the
importance of ISG15 conjugation during viral infection comes from the evolution of viral
proteins that directly target ISG15 conjugate formation. Both the NS1 protein of influenza B
virus and the E3L protein of vaccinia virus inhibit ISG15 conjugate formation, while OTUdomain containing viral proteins, such as the L protein of Crimean-Congo hemorrhagic fever
virus (CCHFV) or the Nsp2 protein of Equine Arteritis virus (EAV), and the SARS coronavirus
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papain-like protease (SARS-CoV PLpro) exert both deubiquitinating and deISGylating activity
(24, 38, 42, 43). Therefore, the antiviral activity of ISG15 has been thought to be conjugation
dependent.

Herein we demonstrate that despite an increased susceptibility of neonates to CHIKV
infection, they produce robust levels of type I IFNs. While insufficient to completely control
infection, IFNs participate in limiting the infection. We also show that ISG15 is induced during
CHIKV infection and plays a critical role in protecting neonatal mice from viral induced
lethality. Surprisingly, the mechanism of action by which ISG15 limits infection is independent
of UbE1L mediated conjugation, as UbE1L-/- mice displayed no phenotypic differences as
compared to wild-type animals. Furthermore, ISG15 does not directly inhibit viral replication, as
suggested by the similar viral loads in WT and ISG15-/- mice. Instead, ISG15 appears to function
as an immunomodulatory molecule in this model. These data demonstrate a novel role for ISG15
during viral infection and suggests that prophylactic measures targeting the induction of IFN and
ISG15 may help protect neonates during future CHIKV outbreaks.
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Results
CHIKV infected infants produce high levels of IFN and IFN-induced chemokines/
cytokines.
Based on the increased severity of neonatal disease that has been observed during the recent
epidemic of CHIKV, we assessed the inflammatory response of infants during the acute phase of
CHIKV infection. Patients were recruited at the time of presentation in the emergency room and
sera samples were collected and stored. CHIKV infection was confirmed by RT-PCR; and all
patients were negative for anti-CHIKV IgG and IgM, indicating acute infection. We performed
multi-analyte testing using Luminex technology, with a focus on inflammatory cytokines and
chemokines. The inflammatory signature was compared to uninfected patients presenting to the
emergency room for reasons unrelated to acute infection (e.g., broken bone). The intensity of the
immune response in the infant vs. adult cohorts was compared. Non-parametric tests were used
for the statistical analysis, and a false discovery rate (FDR) correction was applied to all p-values
in order to adjust for multiple testing.
We detected elevated levels of both IFNα and IFNγ in both groups of patients when
compared to their respective control group (p < 0.005). Interestingly, both IFNα and IFNγ levels
were more elevated in infants in comparison to adult patients (Fig. 2.1A). In addition, the
chemokines/cytokines known to be induced by IFNs were highly expressed. These included
CCL2, CCL4, CXCL9, CXCL10, IL-1Rα, IL-12p40/p70; and strikingly these analytes, with the
exception of CXCL9, showed higher plasma concentrations in infants as compared to adult
patients (Fig. 2.1B). Despite the clinical presentation including fever (Table S2.1), levels of the
pyrogenic cytokines IL-1β and TNFα were not significantly elevated in patients when compared
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to their controls; with only IL-6 being slightly upregulated in adult patient as compared to the
control group (data not shown). Also of interest, while we observed marked induction of socalled Th1 cytokines, such as IFNγ and IL-12p40/p70, there was no clear skewing toward a Th1
response. In fact, we observed high levels of Th2 cytokines as well as Th17 cytokines (Fig.
2.1C). Notably, these interleukins were upregulated as compared to healthy individuals, but were
similarly expressed in the infected infant and adult groups. These data suggest that infants, while
developing more severe manifestations of CHIKV, do indeed mount a robust acute response to
infection.
One potential caveat to this conclusion is that the viral load is higher in infants, possibly
accounting for greater immune activation (median viral load in infants = 1.6 x 108 RNA copies;
median viral load in adults = 1.4 x 107 RNA copies). Within the infant group, viral load
negatively correlated with age, corroborating the observation that newborns are more susceptible
to CHIKV induced disease (Fig. 2.2A). In adults, there was also an age-dependent trend with
elderly harboring higher viral loads (Fig. 2.2A). Again this is consistent with the report that
increased age is a risk factor for severe CHIKV disease (44). Next, we plotted plasma IFNα
concentrations as a function of age. These data demonstrate a strong negative correlation in
infants, and followed the pattern seen for CHIKV titers (Fig. 2.2B). We found that IFNα levels
correlated with viral loads in both group (Fig. 2.2C). To normalize for CHIKV titers, we
separated each cohort in two groups (< global median : low viral load; and > global median :
high viral load), in both groups the levels of IFNα were more elevated in infected infants than in
infected adults (Fig. 2.2D). Furthermore, we performed univariate linear regression analysis to
model the effect of infant status on plasma IFNα concentrations. Infants had higher IFNα
concentrations compared to adults (RGM [95% CI] = 5.49 [3.16 - 9.53]; p<0.001). This effect
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remained significant after adjustment for viral load (adjusted RGM [95% CI] = 3.44 (2.07 5.70]; p<0.001). Thus for a similar viral load, infants produce more IFNα than adults. To
represent associations between age, viral load, IFNα and the immune signature, we established a
network plot of significant correlations (Fig. 2.2E). These data argue against infants being
compromised in their response to CHIKV infection; however, we could not determine whether
their IFN response was protective. To address this issue and to examine the mechanism of ISG
mediated control of CHIKV, we exploited a recently described neonatal mouse model for
studying infection (15).

CHIKV infection in neonatal mice results in a robust type I interferon and
proinflammatory cytokine response that is critical in controlling infection.
Previously, we reported an age-dependent susceptibility to CHIKV infection in mice. Infection
of 6 day old animals resulted in 100% mortality; 9 day old animals developed paralysis, with
approximately 50% of the animals succumbing to infection; while by 12 days of age the mice
became refractory to symptoms of severe disease and lethality (15). To compare our
experimental mouse model of CHIKV infection to the response seen in human infants we
assessed the IFN and proinflammatory responses in 8-9 day old mice. We first assessed the
induction of the IFN response at the local site of infection by monitoring mRNA levels of
2
x 105 PFU of CHIKV and the injection site was removed between 3–120 hrs post-infection.
Increased expression of IFNβ mRNA could be detected as early as 3 hrs post-infection with peak
levels being achieved at 16 hrs post-infection (Fig. 2.3A). Similar to IFNβ mRNA induction,
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IRF7, Mx1 and ISG15 mRNA levels could also be detected as early as 3 hrs post-infection, with
peak levels observed at 16 hrs post-infection (Fig. 2.3A). Thus, at the site of infection, neonatal
mice are able to induce IFNβ expression as well as a subset of known ISGs. Of note, IRF7 and
Mx1 mRNA expression is indicative of signaling via the type I IFN receptor, suggesting that the
production as well as reception of IFNαβ is intact in neonatal mice.
We next assessed the systemic inflammatory response in this model. Similar to our
findings in human infants infected with CHIKV, we observed a strong induction of IFNα and
IFNγ in infected pups (Fig. 2.3B). Plasma concentration of CCL2, CCL4, CXCL9 and CXCL10
were also elevated, however IL-12p70 was only modestly induced (Fig. 2.3C). Similar to the
human data, a mixed Th1, Th2 and Th17 cytokine profile was observed with the induction of IL12, IL-5, IL-13, IL-15, and IL-17 (Fig. 2.3C). For all analytes, peak levels were seen 16–24h
post-infection (Fig. 2.3). Notably, there were some differences seen between the murine neonate
and human infant inflammatory profiles. Most interestingly, the mice displayed increased levels
of the pyrogenic cytokines, including IL-1β, IL-6 and TNFα, which were not seen in our studies
of human infants (Fig. 2.3C). While this may represent differences in pathogenesis, we believe it
is more a reflection of the fact that the mice can be assessed within hours of viral inoculation,
while the exact timing of the human infection is unknown. Overall, we find that the similarities
between the mouse and human responses support the use of neonatal mice to study the response
to CHIKV infection, and indicate that induction of IFNs, as well as the triggering of an ISG
response, are both rapid and robust.
Next, to confirm that endogenous IFN contributes to the control of CHIKV in neonatal
mice, mice lacking subunit 1 of the type I IFN receptor (IFNAR-/-) mice were infected with
CHIKV at 9 days of age. Consistent with our previous observations in adult mice (15), neonatal
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pups lacking IFNAR were highly susceptible to CHIKV infection with 100% of the pups dying
by day 2 post-infection (Fig. 2.4A). These pups developed a rapid, disseminated infection.
Within 1 day of infection, the IFNAR1-/- mice displayed viral loads at the injection site that were
100-fold higher than that detected in WT controls. We also observed a striking increase in viral
titers in the serum and multiple organs, including the brain, liver, and lung (Fig. 2.4B). These
data indicate that endogenous IFN, while insufficient to protect mice, plays an important role in
limiting CHIKV infection during disease pathogenesis in neonatal animals.

Pre-treatment with Poly I:C prevents clinical disease and CHIKV induced death.
Our results suggest that signaling via the IFNαβ receptor in neonatal mice results in the
robust induction of at least a subset of ISGs and interferon-induced serum proteins (Fig 2.3), and
that the absence of IFNAR results in exacerbated infection and rapid death (Fig. 2.4). One
potential explanation is that neonates possess a developmental delay in their IFN-response that
makes them susceptible to infection as compared to adult animals. It was therefore important to
determine whether prophylactic innate immune responses could protect neonatal animals from
CHIKV infection. To evaluate this question, we injected mice with 25 µg of poly I:C (pIC), a
known inducer of type I IFN, and 1 day later mice were challenged with 2 x105 PFU of CHIKV.
At 7h post treatment with pIC, robust levels of IFNα were detected in the serum of neonatal mice
(Fig. 2.5A). Following CHIKV infection, mice were monitored daily for the development of
symptoms and followed for lethality. Remarkably, 96% of the pIC treated mice survived, in
contrast to only 40% of control mice (Fig 2.5B). Treatment with pIC also prevented CHIKV
induced paralysis, with only 7% of the pIC treated mice developing paralysis during the course
of the infection, as compared to 84% in the control group (Fig. 2.5C). Independent experiments

39

were performed using prophylactic treatment with 5000 U IFNβ. At both day 7 and day 11 postinfection, mice receiving recombinant IFNβ displayed less severe disease, as compared to control
PBS injected animals (Fig. S2.1), however, we did not see a statistical difference in survival,
possibly due to the short half-life of IFNβ. To confirm that the protection induced by pIC was
mediated by IFN, we repeated these experiments in IFNAR-/- mice. As seen in Figure 2.5D,
treatment of IFNAR-/- mice with pIC resulted in no protection from lethality. These results
indicate that the prophylactic engagement of the IFN receptor in neonates is able to induce a
protective anti-viral response.
ISG15 plays a significant role in the control of neonatal CHIKV infection.
Interferons mediate their antiviral activity through the induction of ISGs, thus suggesting
that investigation of the downstream effector molecules may offer additional insight into how
neonates respond to CHIKV infection. The analysis of selected ISGs expressed at the site of
infection revealed that ISG15 mRNA was rapidly and strongly induced during CHIKV infection
(Fig. 2.3A). ISG15 is an ubiquitin-like molecule that conjugates to both host and viral proteins
and has been previously shown to participate in the host response to SINV infection. An
evaluation of ISG15 protein expression at the site of infection and within the serum confirmed
that ISG15 and ISG15 conjugates were induced during CHIKV infection in WT mice (Fig.
2.6B,C). As we previously described during neonatal SINV infection [45], the expression of
ISG15 during CHIKV infection was also dependent upon intact IFN signalling since IFNAR -/pups infected with CHIKV did not induce detectable levels of ISG15 (Fig. S2.2). To test the
hypothesis that ISG15 is important in the control of CHIKV, we infected ISG15-/- neonatal mice,
comparing them to weight and age-matched WT control animals. Mice were followed daily for
signs of illness and survival. As reported above, infection of 9 day old WT neonatal mice
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resulted in 58% lethality, with deaths occurring between days 10-13 post-infection. In contrast, a
dramatic increase in lethality was observed in neonatal mice lacking ISG15, with greater than
70% of the ISG15-/- mice succumbing to infection within 3 days, and 100% of the mice dying by
day 9 post-infection (Fig. 2.6A).
It has been previously shown that WT mice become resistant to CHIKV induced lethality
between 9 to 12 days of age, while mice lacking IFNAR1 remain susceptible to infection even as
adults. Since ISG15 is an IFN-induced protein we next determined if its activity was age
dependent. We infected either WT or ISG15-/- mice at 11 or 12 days of age, or we infected adult
mice between 6-8 weeks of age. By 11 days of age the WT mice had become largely resistant to
CHIKV induced lethality with only 15% of the mice succumbing to infection (Fig. S2.3A). In
contrast, we observed 100% lethality in the ISG15-/- mice, although the onset of lethality was
delayed, with the majority of the mice dying between 10 and 14 days post-infection. By 12 days
of age the ISG15-/- mice still showed clinical signs of disease, with a dramatic decrease in weight
gain as compared to the WT controls (data not shown), but by this age only 20% of the ISG15 -/mice succumbed to the infection (Fig. S2.3B). Strikingly, adult ISG15-/- mice, similar to WT
controls, displayed no lethality and showed no signs of disease following CHIKV infection (Fig.
S2.3C). Therefore, we conclude that ISG15 contributes to the control of CHIKV during neonatal
infection, but redundant mechanisms are responsible for the control of CHIKV during adult
infection.
Since IFNs induce the expression of many ISGs, we next wanted to investigate if ISG15
contributed to the protective anti-viral response established by prophylactic induction of type I
IFN. WT or ISG15-/- mice were treated with 10 - 25µg of pIC and 1 day later challenged with 2
x105 PFU of CHIKV. Not unexpectedly, pretreatment with pIC offered protection to both WT
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and ISG15-/- mice. After pretreatment with 25μg of pIC, 14% of the ISG15-/- mice still
succumbed to infection as compared to complete protection seen in the WT mice (Fig. 2.6D).
Interestingly, only 50% of the ISG15-/- mice were protected after pretreatment with 10μg pIC, as
compared to 85% protection observed in the WT mice (Fig. 2.6E). These data support our
observation that ISG15 is induced as part of the IFN response and that it plays an important role
during CHIKV infection.
ISG15 controls neonatal CHIKV infection independent of UbE1L mediated conjugation.
We next investigated the mechanism by which ISG15 protects neonatal mice from
CHIKV infection. We had previously shown that the conjugation of ISG15 to target proteins is
essential for the control of several viral infections (40, 41). UbE1L is the only identified E1 for
ISG15, and mice lacking UbE1L express free ISG15, but fail to form ISG15 conjugates (39). To
establish a role for ISG15 conjugation, 9 day old UbE1L-/- mice were infected with CHIKV.
Surprisingly, UbE1L-/- mice displayed no increase in lethality following CHIKV infection, and
instead had a lethality curve similar to that observed in WT mice (Fig. 2.6A). Similarly, pIC
treated UbE1L-/- mice were protected to the level of WT controls (Fig. 2.6D, E). Western blot
analysis on skin/muscle from the site of infection (Fig. 2.6B), as well as serum (Fig. 2.6C), was
used to confirm that UbE1L-/- mice generated no ISG15 conjugates during CHIKV infection,
whereas WT mice showed robust conjugate formation. Additional organs (lung and liver) were
also examined and no conjugates were detected in UbE1L-/- mice (data not shown). Thus, we
demonstrate that the activity of ISG15 during CHIKV infection is UbE1L independent.
In an attempt to provide additional evidence that unconjugated ISG15 was functioning in
this model, we generated recombinant double subgenomic CHIK viruses that expressed either
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WT ISG15 (CHIK- LRLRGG) or a mutant, non-conjugatable form of ISG15 (CHIK- LRLRAA)
(Fig. S2.4A). This strategy was based on our previous report in which recombinant SINV
expressing WT ISG15 (LRLRGG) rescued the increased lethality observed in the ISG15 -/- mice,
while mutant ISG15 (LRLRAA) failed to compensate for the ISG15 deficiency (34, 40). Both
CHIK-LRLRGG and CHIK-LRLRAA expressed ISG15 and displayed similar growth kinetics to
CHIK-GFP in BHK cells (Fig. S2.4B, 4C). When we infected ISG15-/- mice, however, neither
CHIK-LRLRGG nor CHIK-LRLRAA was able to protect ISG15-/- mice (Fig. S2.4D and data not
shown). While these results do not allow us to confirm that the activity of ISG15 is independent
of conjugation, they do suggest that the mechanism of action of ISG15 during SINV and CHIKV
infection are distinct.
To further evaluate the mechanism by which ISG15 functions during neonatal CHIKV
infection we examined lymphocyte subsets and viral titers in WT, UbE1L-/- and ISG15-/- mice.
We detected no significant differences in the lymphocyte subsets of naïve neonatal WT, UbE1L/-

and ISG15-/- mice (Table S2.2). Similar results have been observed in both naïve and pIC

stimulated adult mice (39, 45). These data suggest that differences in starting cell populations do
not account for the increase in lethality observed in ISG15-/- mice. We next assessed viral titers
on days 1 and 2 post-infection. As expected, UbE1L-/- mice displayed similar viral loads in
multiple tissues when compared to WT mice at days 1 and 2 post-infection (Fig. 2.7A and B).
Given that the ISG15-/- pups infected at 9 days of age displayed a dramatic increase in lethality,
with kinetics similar to that observed in the IFNAR-/- mice, we expected to detect increased viral
titers in the ISG15-/- mice. To our surprise, at 1 day post-infection the serum and tissues analyzed
from the ISG15-/- mice contained viral titers that were similar to those obtained in both UbE1L-/and WT mice (Fig. 2.7A). This was in striking contrast to the 2-3 log increase in viral loads
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detected in the IFNAR-/- mice 1 day post-infection (Fig. 2.4B). By 2 days post-infection, just
prior to when the majority of ISG15-/- mice succumb to infection, we still detected similar viral
loads between WT, UbE1L-/- and ISG15-/- mice in the analyzed tissues (Fig. 2.7B). Based on
these data we suggest that ISG15 may not be playing a direct anti-viral role, but instead may be
acting via an unexpected mechanism of regulating host sensitivity to the viral induced immune
response.
Since our evaluation of human infants and neonatal mice demonstrated that CHIKV
infection induces a robust proinflammatory cytokine and chemokine response (Fig. 2.1 and 2.3),
we investigated the impact of ISG15 deficiency on this host response. IFNβ mRNA levels were
induced in the skin of WT, UbE1L-/- and ISG15-/- mice at 24 and 48hrs post infection with no
significant differences noted between the three strains of animals (Fig. 2.8A). Serum from WT,
UbE1L-/- and ISG15-/- mice collected at 1 or 2 days post-infection were analyzed for IFNα as
well as proinflammatory cytokines and chemokines. Analysis of IFNα serum levels also revealed
no significant differences between WT, ISG15-/-, and UbE1L-/- mice at either 24 or 48 hrs postinfection (Fig. 2.8B). Despite similar viral loads and type I IFN induction, the ISG15-/- mice
displayed elevated levels of TNFα, IL-1β and IL-6 as compared to both the WT and UbE1L-/mice (Fig. 2.8C). Interestingly the levels of these three pyrogenic cytokines in the ISG15-/- mice
were comparable to what was observed in the IFNAR-/- pups, despite the latter having
significantly higher viral loads. ISG15-/- mice also displayed elevated chemokine levels,
including CCL2, CCL3 and CCL5 (Fig. 2.8C). Therefore, although viral titers between ISG15-/-,
UbE1L-/- and WT mice are similar, ISG15-/- neonates display an exaggerated proinflammatory
cytokine response to CHIKV infection. Together, these data indicate that ISG15, independent of
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UbE1L mediated conjugation, is contributing to the control of CHIKV infection by blunting
potentially pathologic levels of innate effector molecules.
Elevated pro-inflammatory cytokine levels likely contribute to the increased lethality seen
in CHIKV infected neonatal ISG15-/- mice.
We hypothesized that the exaggerated cytokine response displayed in ISG15-/- mice
during CHIKV infection could contribute to the increased lethality in ISG15-/- compared to WT
and UbE1L-/- mice. The levels of TNFα observed were similar to what has been previously
reported in adult models of LPS induced septic shock (46, 47) as well as neonatal Sindbis virus
infections (48), where mice are thought to die from a cytokine storm. Consistent with a cytokine
storm phenotype, no striking differences in histology (H&E) were found between the three
genotypes, although necropsy analysis revealed that ISG15-/- had more severe blood vessel and
airway injury than WT and UbE1L-/- mice (data not shown). To support our findings, we also
performed a blood chemistry analysis on serum collected on day 2 post CHIKV infection from
WT, UbE1L-/- and ISG15-/- neonatal mice. Blood chemistry analytes can be used to assess the
function of the liver, kidneys, heart, pancreas and other organs. Alteration in blood analyte levels
(ALT, AST, BUN and Creatinine) can be an indication of multiple organ dysfunction syndrome
(MODS) that can also occur during septic shock (49-51). Preliminary data suggests that WT and
UbE1L-/- mice do not display changes in blood analyte levels compared to PBS treated mock
controls (Figure S2.5). In contrast, we observed elevated levels of ALT, AST, and BUN in
CHIKV infected ISG15-/- mice compared to WT and UbE1L-/- mice (Figure S2.5). We also
observed decreased levels of glucose in ISG15-/- mice. No difference was observed in Creatinine
levels. This data is consistent with our cytokine data (Figure 2.8C) and suggests that CHIKV
infected ISG15-/- may suffer from multiple organ dysfunction. We have also generated
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preliminary data that indicates that pre-treating neonatal ISG15-/- mice with a blocking TNFα
antibody delays CHIKV induced lethality (data not shown). Altogether, our data supports the
hypothesis that elevated cytokine levels contributes to increased lethality in CHIKV infected
neonatal ISG15-/- mice.
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Discussion
The ongoing epidemic of Chikungunya virus occurring in the Indian Ocean region has
highlighted how little we understand about the pathogenesis of this virus. Epidemiological
studies have provided the first documentation of vertical transmission, as well as providing
detailed information about the severity of disease and long term sequelae (4, 52-54). One
important finding from these studies concerns the increased susceptibility of neonates and infants
to severe forms of Chikungunya disease (10, 44, 55). In this study, we evaluated the response of
infants to CHIKV infection using data from both human samples collected during the La
Réunion outbreak, as well as taking advantage of a newly described mouse model of infection.
Our results show that human infants and murine neonates mount a robust innate immune
response to CHIKV infection, which includes the induction of type I IFNs, several cytokines and
chemokines, and the induction of at least a subset of IFN induced genes, including ISG15. We
establish a role for ISG15 in the pathogenesis of CHIKV infection with an absolutely essential
role in the neonatal response to infection. Moreover, and to our surprise, the reported data
suggest that ISG15 acts independently of UbE1L mediated conjugation and rather than exerting a
direct anti-viral role, it appears to be implicated in limiting an exaggerated inflammatory
response.
In general, neonates are more susceptible to microbial and viral infection. This
vulnerability has been explained by two principal mechanisms: broader tropism of the infectious
agent or a defective host response. Regarding the latter, many argue that neonatal susceptibility
to infection is due to a delayed or weaker immune response (16, 56). Factors contributing to this
include delays in immune system maturation, decreased expression of activation receptors, or
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distinct regulation of signaling pathways in neonatal vs. adult immune cells. Since the type I
IFN response is critical for controlling CHIKV infection (15, 20), we hypothesized that neonates
may have a defect in their ability to either produce and/or respond to IFN. Instead, we observed
that the production of type I IFN was intact in both human infants and mouse neonates.
Furthermore, the relative level of IFN produced in infants was higher than the responses
observed in adult human patients, even when viral load was normalized between the two patient
groups (Fig. 2.1). These data indicate that neonates do not have a defect in their ability to
produce type I IFN during CHIKV infection, and may actually be hyper-responsive. Very little
has been reported on the signaling through RLRs or other viral sensors in neonates. Most
previous work has supported the notion that signaling through TLR receptors, including TLR4,
are diminished in neonates (57, 58). However, one study did find that neonatal mice exhibited
increased lethality following LPS treatment, due in part to an exaggerated pro-inflammatory
cytokine response as compared to adult mice (59). Future work is needed to characterize
differences that may exist between neonatal and adult RLR signaling.
We also demonstrate that neonates can respond to the IFN that is produced. In both
human infants and in neonatal mice, several known IFN-induced chemokines and cytokines were
upregulated during the course of infection (Fig. 2.1-3). These results suggest that the ability to
respond to IFNs was at least partially intact. These observations were confirmed by
demonstrating the greater susceptibility of neonatal mice lacking expression of the type I IFN
receptor (Fig. 2.4); notably, the kinetics of viral replication and death were massively accelerated
as compared to age-matched WT controls. Additionally, we demonstrate that the prophylactic
exposure to an interferon-inducing adjuvant protected animals from challenge with lethal doses
of CHIKV (Fig. 2.5).
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To provide insight into the mechanism by which IFN participates in the host response to
CHIKV infection, we evaluated the role of ISG15, an anti-viral host protein that has previously
been shown to be important in the control of several viruses, including SINV (34). We found that
ISG15-/- mice were more susceptible to CHIKV infection, demonstrating a dramatic increase in
lethality as compared to WT mice (Fig. 2.6A). Moreover, ISG15 played a critical role in pIC
induced protection of mice in a prophylactic setting (Fig.2.6D, 2.6E). While OAS has previously
been shown to inhibit viral replication when over-expressed in vitro (60), to our knowledge our
data is the first in vivo demonstration of an IFN effector molecule having activity against
CHIKV.
Most importantly, the results from our current study indicate that ISG15 is regulating
CHIKV pathogenesis by a unique mechanism of action. First, we demonstrate that ISG15
regulates CHIKV infection independent of UbE1L mediated conjugation. This is in contrast to
both influenza virus and SINV infection, where the anti-viral activity of ISG15 is dependent
upon ISG15 conjugation and abrogated in UbE1L-/- animals (40, 41). The protection mediated
by ISG15 during pIC prophylaxis also appeared to be UbE1L independent, as UbE1L-/- mice
displayed survival curves similar to WT mice (Fig. 2.6D, 2.6E). These results suggest that the
non-classical function of ISG15 is at work both during acute viral infection and in the pIC
induced protection seen in our mice. UbE1L is the only known E1 for the ISG15 pathway, and
our analysis of the UbE1L-/- mice revealed no conjugation activity post-infection (Fig. 2.6 and
(39)). Therefore the actions of ISG15 during CHIKV infection are likely to be independent of
conjugation, and mediated by free ISG15. One alternative explanation may be the involvement
of a second E1, as has been identified for the ubiquitin pathway (61). Second, it appears that
during CHIKV infection, ISG15 is not functioning as a direct antiviral molecule. In both the
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influenza and SINV models, the increase in lethality was accompanied by a dramatic increase in
viral loads (34, 38, 41). In contrast, during CHIKV infection, ISG15-/- mice did not show an
increased CHIKV burden (Fig. 2.7). Instead, we noted a significant elevation of several
proinflammatory cytokines and chemokines in the ISG15 deficient mice (Fig. 2.8). Therefore, as
opposed to having direct antiviral activity, it appears that ISG15 modulates the immune response
during CHIKV infection. Finally, in contrast to what was previously reported for control of
SINV infection (34), a recombinant CHIKV expressing ISG15 was unable to rescue neonatal
ISG15-/- mice from viral induced lethality (Figure S4). The inability to rescue the ISG15-/phenotype may be due to insufficient expression levels of ISG15; the timing of ISG15 expression
may be delayed as compared to WT mice; or may in fact indicate that ISG15 expression is
required in an uninfected cell. Since we detect no differences in viral load, and instead observed
increased cytokine levels in the ISG15-/- mice, we favor this later possibility. Further analysis
into the precise mechanism by which ISG15 regulates the host response to CHIKV should
provide additional insight into this issue. Together, our data suggest a novel mechanism for
ISG15, which is likely to be independent of conjugation and extrinsic to virally infected cells.
The precise mechanism by which ISG15, independent of UbE1L mediated conjugation,
contributes to the control of viral infection is currently unclear. The most intriguing difference
we have noted to date is the increased cytokine responses in the mice lacking ISG15 (Fig. 2.8).
As noted above, while we cannot formally exclude the possibility of another E1 functioning in
this system, it seems most likely that free, unconjugated ISG15 mediates the activity during
CHIKV infection. Free ISG15 is found within the cell, but interestingly it may also be secreted
by a still undefined mechanism (33). Previous work has shown that unanchored ISG15 can
associate non-covalently with proteins (i.e. independent of conjugation). For example, the NS1
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protein of influenza B virus can non-covalently bind ISG15, thereby inhibiting its interaction
with UbE1L and blocking conjugation of target proteins (24). The over-expression of ISG15 has
also been shown to disrupt Nedd4 ligase activity and inhibit Ebola virus VLP release (62, 63).
Recent research within the ubiquitin field has described a role for unanchored polyubiquitin
chains, shown to regulate TRAF6 function, as well as promote RIG-I dimerization and signaling
(64, 65). It is therefore possible that intracellular, unanchored ISG15 interacts non-covalently
with members of an innate immune signaling pathway to regulate cytokine and chemokine
production or other host response pathways. Alternatively, released ISG15 could be contributing
to the phenotype seen during CHIKV infection. Indeed, the 17 kDa form of ISG15 is released
into the serum in both WT and UbE1L-/- mice during CHIKV infection (Fig. 2.6). Released
ISG15 has been reported to function as an immunomodulatory molecule, increasing NK cell
proliferation and lytic activity, acting as a neutrophil chemoattractant, and upregulating Ecadherin expression on dendritic cells (35-37). Released ISG15 could function as in
immunomodulatory cytokine by signaling through a receptor to regulate the cytokine response or
through its ability to function as a chemoattractant. In order to characterize these effects in
greater detail, a receptor for ISG15 must be identified. Future studies evaluating these
possibilities will be required in order to further define the mechanism by which ISG15 is
contributing to the host response to CHIKV.
Although we do not understand mechanistically why ISG15-/- mice display elevated
cytokine levels during CHIKV infection, our data indicates that this cytokine increase is
biologically significant. During neonatal Sindbis virus infection, mice are thought to succumb to
infection due to a cytokine storm (48). The lack of alterations in major organ histology and the
levels of TNFα produced in our CHIKV model are consistent with what has been described for
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SINV. We also provide additional evidence that CHIKV infected ISG15-/- mice may suffer from
multiple organ dysfunction syndrome (MODS), another readout for septic shock, as indicated by
altered blood chemistry levels (Fig. S2.5) (49). Therefore, elevated cytokine production
contributes to the increased lethality in ISG15-/- mice. Cytokine production may be a relevant
readout for future functional studies to understand the mechanism of ISG15 mediated host
regulation.
In conclusion, we have demonstrated that neonates are capable of producing type I
interferon in response to CHIKV, which serves to limit viral infection though remains
insufficient to clear the virus. We have demonstrated a critical, age-dependent role for ISG15
during neonatal infection. We have also characterized the mechanism of ISG15 activity,
revealing a novel mechanism for ISG15, independent of UbE1L mediated conjugation, and
functioning as a putative immunomodulator of proinflammatory cytokines. The ability of pIC to
protect neonatal mice against CHIKV infection suggests that manipulation of the IFN signaling
pathway, and perhaps the induction of ISG15, may be an appropriate therapeutic target for
combating CHIKV infection.
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Materials and Methods

Ethics Statement
All human studies were approved by the Committee for Clinical Research at the Institut Pasteur,
project number RBM 2009-23, on July 9, 2009. Written informed consent was obtained from the
study participants or legal guardians. For mouse studies at the Institut Pasteur and at Washington
University, the principles of good laboratory animal care were carried out in strict accordance
with the recommendations in the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health and following the International Guiding Principles for Biomedical
Research Involving Animals. The protocols were approved by the Animal Studies Committee at
Washington University (#20090287) and the Institutional Committees on Animal Welfare of the
Institut Pasteur (OLAW assurance # A5476-01). All efforts were made to minimize suffering.

Human Study
Retrospective study on patients who presented to the emergency or pediatric service of the
Groupe Hospitalier Sud Réunion, Saint Pierre, La Réunion, France from January 2006 through
May 2006. Sera samples were collected and stored at -80°C. CHIKV infection was confirmed
by RT-PCR. All patients were negative for anti-CHIKV IgG and IgM as assessed by
immunocapture Elisa. The control cohort consisted of patients that presented to the orthopedic
chirurgy or infant chirurgy service of the Groupe Hospitalier Saint Pierre before the epidemic.
These patients were IgG, IgM and RT-PCR negative for CHIKV. Data from adult patients were
previously reported (20), but are shown here for comparison to data from infected neonates.
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Virus
The preparation of CHIKV from clinical samples has been previously described (66). CHIKV
(06.21) strain was isolated during the epidemic in La Réunion and then propagated three time on
C6/36 mosquito cells to generate a stock (6x107 PFU/mL) that was used in all experiments.
Recombinant CHIKV strains. The generation and characterization of a recombinant double
subgenomic CHIKV virus expressing GFP, CHIKV-LR 5’ GFP, has been previously described
(67). Recombinant CHIKV expressing ISG15 were generated as follows.
(i)

ISG15 LRLRGG. Nucleotides 1 to 465 of murine ISG15 were PCR amplified using a 5’
primer that introduced an AscI restriction site and a 3’ primer containing GGT GGG
TAA sequence and a PmeI site.

(ii)

ISG15 LRLRAA. Nucleotides 1 to 465 of murine ISG15 were PCR amplified using a 5’
primer with an AscI restriction site and a 3’ primer containing GCG GCG TAA sequence
and a PmeI site.

The correct sequence for each virus was confirmed. Generation of recombinant ISG15 viruses
was previously described (68). Viral stocks were generated by in vitro transcription of linearized
cDNA templates, followed by transfection of the transcripts with Lipofectamine (Invitrogen) into
BHK cells. Supernatants were harvested 48 hrs post transfection and viral titers were determined
by plaque assay as described below. To examine growth characteristics of the recombinant
viruses, BHK cells were infected at a multiplicity of infection (MOI) of 1.0 and viral titers were
measured at various times post-infection. To determine the expression of ISG15 from
recombinant viruses, BHK cells were infected at an MOI = 1.0 and at various times postinfection total cell lysates were harvested and ISG15 expression was analyzed by Western blot
analysis.
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Mice
Experiments in mice were carried out at both the Institut Pasteur, Paris, France and at
Washington University School of Medicine, St. Louis, Missouri, using the identical CHIKV viral
stock described above. Infection of 9 day old pups with 2 x 105 PFU subcutaneously (s.c.)
resulted in approximately 50-60% lethality in WT mice at both locations. For experiments
carried out at the Institut Pasteur, eight day old C57BL/6 litters were obtained from Charles
River laboratories (France). For experiments carried out at Washington University, mice were
maintained at Washington University School of Medicine in accordance with all federal and
University guidelines. ISG15-/- mice were provided by Dr. Ivan Horak and Dr. Klaus-Peter
Knobeloch. UbE1L-/- mice were provided by Dr. Dong-Er Zhang. The generation of both the
ISG15-/- and UbE1L-/- mice has been previously described (39, 45). C57BL/6, IFNαβ receptor 1
(IFNAR1-/-), UbE1L-/- and ISG15-/- mice, all on the C57BL/6 background, were bred and
maintained in our mouse colony. Congenic SNP analysis (Taconic laboratories) of UbE1L-/- and
ISG15-/- mice confirmed that these mice were fully backcrossed, with 99.93% and 99.72%
identity to C57BL/6 mice, respectively. For neonatal experiments mice were infected between 9
and 12 days of age as indicated. Litters were weight matched at the initiation of the experiments.
For adult experiments, mice were infected between 6-8 weeks of age and were age and sex
matched within experiments.

Viral studies
For neonatal experiments using the clinical isolate of CHIKV, 9 day old pups were infected with
2.0 x 105 PFU CHIKV in 20-30 µL of PBS by injection subcutaneously (s.c.) into the right flank.
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Infected mice were followed daily for weight gain, signs of disease, and lethality for 21 days
post-infection. Paralysis was scored as an inability or long delay (>5s) to return and land on its
feet when flipped on its back. For experiments with adult mice, 6-8 week old mice were infected
as outlined above and followed for daily weight loss and lethality. For experiments utilizing the
recombinant CHIKV clones, 6 day old pups were infected with 3 x 105 PFU of the indicated
recombinant virus diluted in 30 μL of PBS by s.c. injection into the right flank. Viral titers were
determined in organs harvested at the indicated days post-infection. Organs were harvested into 1
ml of DMEM without fetal bovine serum and homogenized with 1.0 mm diameter zirconia-silica
beans at 3,200 rpm for 1 minute with a MagnaLyzer prior to plaque assay on BHK cells, protocol
modified from (69). Serial dilutions of organ homogenates in DMEM with 1% FBS was added to
BHK cells (6x105 cells for 6 well plates) and incubated for 1hr at 37⁰C. An agar overlay was
then added to the cells and incubated for 28hrs at 37⁰C. Plates were fixed with 1% formaldehyde
(>30min at room temperature), agar plugs were removed and plaques were visualized using a 1%
crystal violet solution.

Poly I:C prophylactic treatment studies
Eight day old mice were injected intraperitoneally (i.p.) with 10-25µg of high molecular weight
polyI:C (Invivogen). Twenty-four hours later, mice were challenged with 2 x 105 PFU CHIKV
s.c. Mice were monitored daily for the development of symptoms and followed for lethality as
described above.

Cytokine and blood chemistry analysis
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Sera were harvested and conserved at -80ºC for analysis. Human cytokines were measured by
Luminex (25 plex kits, Biosource, Invitrogen) following manufacturer’s instructions. Human
CXCL10 was re-titrated by ELISA (human quantikine ELISA kit, R&D). Mouse sera were
obtained after coagulation of blood in T-MG tubes (Terumo). Mouse IFNα levels were
quantified by ELISA (PBL biomedical) and other cytokines were measured using Luminex
technology with either the 32 plex from Millipore (MPXMCYTO-70X) or by customized 10
plex from Biorad. Blood chemistry analytes were processed by the DCM core facility at
Washington University in St. Louis.

qRT-PCR for quantification of viral load and IFN mRNA
For determination of patient viral load, total nucleic acid extraction was performed on sera in a
MagNa Pure automate using the Total Nucleic Acid Kit (Roche Diagnostics). CHIKV RNA was
detected with specific taqman probes using a one step RT-PCR (Master RNA hybridization
probes, Roche) performed on a Chromo 4 machine (Biorad). The 20μL reaction mix contained
2μL of extracted RNA, 7.5μL of LightCycler RNA Master Hyb-Probe, 3.25 mmol/L Mn2 , 450
nmol/L CHIKV-forward primer, 150 nmol/L CHIKV-reverse primer, 150 nmol/L CHIKV Probe
(5 6-carboxyfluorescein-3 TAMRA) (TibMol-Biol). The thermal cycling consisted of a reverse
transcription at 61 °C for 20 min followed by 45 cycles at 95 °C for 5 s and 60 °C for 15 s. The
fluorescence was measured at 530 nm. CHIKV load is measured using a synthetic RNA
calibrator (70). CHIKV-rev CCAAATTGTCCGGGTCCTCCT; CHIKV-forw
AAGCTCCGCGTCCTTTACCAAG; Probe: Fam-CCATGTCTTCAGCCTGGACACCTTTTAMRA.
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For mouse studies, skin tissue was harvested at the site of infection on days 1 and 2 postinfection. Tissue was snap frozen in liquid nitrogen and then homogenized in RLT+ with 0.04M
DTT, and RNA was extracted with the Qiasymphony robot (Qiagen) with a protease step and a
DNase step. The quality and quantity of RNA was evaluated with the Agilent technology, with
the RNA integrity number between 8 and 9.5. Reverse transcription was performed with random
primers (Roche) using Superscript enzyme (Invivogen). cDNA for murine IFN-β and ISG15
were detected using Applied Biosystem Taqman probes (Mm00439546-s1, Mm01705338-s1).
To analyze the relative fold induction of mRNA, GAPD expression levels were determined in
parallel for normalization using the CT method.

Western blot analysis
Nine day old mice were infected with 2x105 PFU CHIKV. Tissue homogenates as well as serum
samples were subjected to protein electrophoresis on a 12% Tris gel. The gel was transferred to a
polyvinylidene fluoride membrane and probed for ISG15 expression using a rabbit anti-ISG15
polyclonal serum (1:5000) as previously described (68). The membrane was then developed with
a horseradish peroxidase (HRP)-conjugated goat anti-rabbit antiserum (Jackson
Immunoresearch, West Grove, Pennsylvania) diluted 1:200,000. For loading controls, the same
blot was re-probed with anti-β-actin mAb (clone AC-74; Sigma) and then developed with a HRP
conjugated goat anti-mouse antibody (Jackson Immuno-Research). All blots were developed
with chemiluminescent reagent (Millipore).

Flow Cytometry
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Spleens were harvested from naïve nine day old WT, UbE1L-/- and ISG15-/- mice (12 mice per
strain). Lymphocyte subsets were stained using the following cell surface markers: CD3, CD4,
CD8, NK1.1, CD19, F4/80 and Gr1. Data is represented as percent of the total cell population
and Kruskal-Wallis test was used to compare the three genotypes.

Statistical analysis
Data were analyzed using the Prism software (Graphpad software). The OMNIVIZ statistical
platform (BioWisdom, Cambridge, UK) was used to perform comparisons among data sets using
nonparametric tests (Mann-Whitney U-test) and false discovery rate (FDR) procedures, a
permutation-based method to correct for the increased probability of obtaining a false positives
among all significant tests (71). Differences were considered significant if p < 0.05.

List of accession numbers in GenBank
IFNγ: NM_008337, CCL2: NM_011333, CCL4: NM_013652, CXCL9: NM_008599, CXCL10:
NM_021274, IL12: NM_008352, IL1Rα: NM_001039701, IL4: NM_021283, IL5: NM_010558,
IL13: NM_008355, IL15: NM_008357, IL17: NM_010552, IFNβ: NM_010510, IRF7:
NM_016850, Mx1: NM_010846, ISG15: NM_015783, IL1β: NM_008361, IL6: NM_031168,
TNFα: NM_013693, IFNAR1: NM_010508, UbE1L: NM_023738.
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Figure 2.1. Serum concentration of IFN and IFN-induced chemokines is higher in CHIKV
infected infants as compared to adults. Patient sera were obtained from acute CHIKV infected
adults (age = 16-86 years) and infants (age = 2-5 months). Age matched controls from La
Réunion were tested. Chemokines / cytokines were measured using a Luminex assay. (A) IFNα
and IFNγ levels; (B) IFN-induced molecules; and (C) Lymphocyte cell derived cytokines are
shown. Whisker-box plots are shown (line indicates median; boxes represent first and third
quartile; and bars define range). Mann-Whitney U-test was performed using a false discovery
rate (FDR) procedure for generating corrected p-values. Comparisons were made between
CHIKV patients versus their control cohort (in black); as well as adult versus infant patients (in
red). ** indicates p<0.005, * indicates p<0.05. IFN data from adult patients were previously
reported (5), but are shown here for comparison to data from infected neonates.
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Figure 2.1
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Figure 2.2. Higher serum IFNα in infants is not explained by differences in viral load. (AC) Correlations between viral load vs. age; IFNα vs. age; and IFNα vs. viral load were evaluated.
CHIKV infected infants are represented by blue squares; CHIKV infected adults are represented
by red circles. Lines indicate linear regression and Spearman correlation (rs) values are shown.
(D) Each group was divided into two subgroups (<median: low viral load or >median: high viral
load; Median = 4.8x107) and statistic are represented (Mann Whitney test) (E) For analytes
identified in Figure 1 that showed a correlation with viral load, IFN or age are plotted in a
network array, illustrating the correlations identified in neonatal vs. adult individuals. Connecting
lines indicate Spearman correlation (rs) values; positive correlations in red and negative
correlations are depicted in blue. IFN data from adult patients were previously reported (5), but
are shown here for comparison to data from infected neonates.
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Figure 2.2
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Figure 2.3. Neonatal mice mount a robust IFN and pro-inflammatory cytokine/chemokine
response following CHIKV infection. Nine day old C57BL/6 mice were injected s.c. in the
right flank with CHIKV. (A) The skin at the site of infection was harvested at the indicated times
post infection and IFNβ, IRF7, Mx1 and ISG15 gene expression was evaluated by qRT-PCR.
The ΔCt was calculated using GAPD as a reference gene. At various time points, sera was
harvested and tested for (B) IFNα by ELISA and IFNγ using Luminex. (C) Serum cytokines and
chemokines were also analyzed using Luminex. Each graph represents 2-3 independent
experiments with 3 mice per experiment.
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Figure 2.3

66

Figure 2.4. Endogenous Type I IFN is required for the control of neonatal CHIKV
infection. WT and IFNAR1-/- mice were infected at 9 days of age with 2x105 PFU CHIKV s.c.
(A) Mice were monitored for lethality for 21 days with data displayed as Kaplan-Meier curves.
(B) Tissue and sera were collected on day 1 post-infection and viral titers were determined using
a standard plaque assay. Mann-Whitney statistical comparison of wild type and IFNAR1-/- viral
titers are shown where * indicates p<0.05, ** p<0.005 and *** p<0.0005, and vertical bars
represent standard error of the mean.
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Figure 2.4
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Figure 2.5. Adjuvant induced type I IFN production protects neonates from CHIKV
infection. Mice (8 days of age) were injected i.p. with 25 µg of poly (I:C) and 24 hours later
mice were infected s.c. in the right flank with CHIKV. (A) IFNα levels produced in the serum of
neonatal mice 7 hours post injection with 25 µg poly (I:C). (B) Survival was monitored daily for
four weeks and displayed as Kaplan-Meier survival curves. (C) Mice were scored for clinical
signs of disease on days 7, 13 and 18 post-infection as discussed in materials and methods. (D)
IFNAR1-/- mice (8 days of age) were injected i.p. with 25 µg of pIC and 24 hours later mice were
infected with CHIKV s.c. Survival was monitored daily.
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Figure 2.5
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Figure 2.6. ISG15, independent of UbE1L, plays a critical role during the neonatal
response to CHIKV. (A-C) WT, UbE1L-/- and ISG15-/- mice were infected with 2x105 PFU
CHIKV s.c. at nine days of age. (A) Mice were monitored for lethality for 21 days with data
displayed as Kaplan-Meier curves. (B) Skin and muscle homogenates from the site of infection
were collected on day 2 post infection and analyzed for ISG15 expression by western blot. (C)
Sera collected on days 1, 3 and 6 p.i. and analyzed as in (B). (D and E) ISG15-/-, UbE1L-/- and
WT mice (8 days of age) were injected i.p. with (D) 25 µg or (E) 10 µg of pIC and 24 hours later
mice were infected s.c. with 2x105 PFU CHIKV. Survival was monitored daily for 21 days and
displayed as Kaplan-Meier survival curves. Mice from all three genotypes that were pretreated
with 25 µg of poly(I:C) and mock infected with PBS showed no lethality (data not shown).
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Figure 2.6
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Figure 2.7. ISG15-/- and UbE1L-/- mice display similar viral loads to WT mice. Nine day old
WT, UbE1L-/- and ISG15-/- mice were injected with 2x105 PFU CHIKV s.c. Tissue and sera were
collected on days 1 (A) and 2 (B) post-infection and viral titers were determined by plaque assay;
vertical bars represent standard error of the mean. A three way comparison of the three
genotypes performed using a Kruskal-Wallis analysis was not significant except for the lung on
day 2 post infection (*, where p < 0.05).
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Figure 2.7
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Figure 2.8. ISG15-/- neonates display elevated cytokine levels during CHIKV infection. Nine
day old WT, IFNAR1-/-, UbE1L-/- and ISG15-/- mice were injected with 2x105 PFU CHIKV s.c.
(A) The skin at the site of infection was harvested and the expression of IFNβ mRNA was
evaluated by qRT-PCR. Vertical bars represent mean with standard error of the mean. (B and C)
Serum was collected at the indicated time post-infection. (B) IFNα levels were quantified using
an ELISA, vertical bars represent mean with standard error of the mean. Statistical comparison
between the three genotypes via Mann-Whitney and Kruskal-Wallis test was not significant for
both (A) and (B). (C) Cytokine and chemokine levels were measured by Bioplex assay (MannWhitney * p < 0.05, ** p < 0.005). Vertical bars represent standard error of the mean.
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Figure 2.8
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Figure S2.1. Pre-treatment with IFNβ improves the outcome of CHIKV infection. Mice 8
days of age were injected i.p. with 5000U of IFNβ and 24 hours later mice were infected s.c. in
the right flank with 2x105 PFU CHIKV. Mice were scored for clinical signs of disease on days 7,
11 and 18 post-infection. The ability of the mice to return and land on its feet when flipped over
was assessed. Paralysis was defined as the inability or delayed time to return (>5s). 3
independent experiments are compiled.
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Figure S2.1
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Figure S2.2. Induction of ISG15 during neonatal CHIKV infection is largely dependent
upon IFNAR1 signaling. Serum from nine day old WT, UbE1L-/-, ISG15-/- and IFNAR-/- mice
infected s.c. with 2x105 PFU CHIKV was collected on day 1 post-infection and ISG15
expression was assessed by western blot.
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Figure S2.2
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Figure S2.3. The role of ISG15 during CHIKV infection is age dependent. WT, UbE1L-/- and
ISG15-/- mice were infected with 2x105 PFU CHIKV s.c. at either (A) eleven days of age, (B)
twelve days of age, or (C) 6-8 weeks of age and were monitored for survival for 21 days postinfection. Kaplan-Meier survival curves are shown.
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Figure S2.3

A

B

C
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Figure S2.4. Recombinant CHIKV viruses expressing WT ISG15 do not rescue ISG15-/mice. Recombinant CHIK viruses were generated to express the following proteins: wild type
ISG15(-LRLRGG), non-conjugatable ISG15(-LRLRAA), and GFP(-GFP). (A) Schematic
representation of recombinant CHIK clones adapted from Tsetsarkin, et al (2006). (B and C)
BHK cells were infected with the indicated rCHIK viruses at an MOI=1. (B) Viral titers were
measured at 0,6,12,24,48hrs p.i. by plaque assay. (C) Cell lysates were collected at 0,6,12, and
24hrs p.i. and were analyzed for ISG15 expression by western blot. (D) Six day old ISG15-/- mice
were infected with either CHIK-GFP or CHIK-LRLRGG at 3x105 PFU s.c. Mice were
monitored for lethality for 21 days with data displayed as Kaplan-Meier curves.
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Figure S2.4

84

Figure S2.5. CHIKV infected ISG15-/- mice have increased ALT, AST, BUN serum levels
and decreased serum glucose levels compared to WT and UbE1L-/- mice. Nine day old WT,
UbE1L-/- and ISG15-/- mice were infected with CHIKV (105pfu s.c.). Serum was collected on day
2 p.i. and sent to DCM for blood chemistry analysis. Analyte levels were compared to PBS mock
treated WT and ISG15-/- controls. * = p<0.05, ** = p<0.01
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Figure S2.5
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Table S2.1. Clinical signs in adult and infant cohort.
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Table S2.2. Splenic lymphocyte subsets in naïve WT, UbE1L-/- and ISG15-/- neonatal mice
(% total cell population, mean ± sem).

Cell Type

WT

ISG15-/-

UbE1L-/-

B cells (CD19+)

9.10 ± 3.0

5.27 ± 2.2

9.08 ± 0.0

NK cells (NK1.1+)

0.43 ± 0.0

0.35 ± 0.0

0.35 ± 0.0

CD4+ T cells (CD4+CD3+)

2.85 ± 0.6

2.15 ± 0.5

2.02 ± 0.1

CD8+ T cells (CD8+CD3+)

1.52 ± 0.3

1.11 ± 0.2

1.13 ± 0.0

Granulocytes (Gr1 hi,F4/80low)

3.02 ± 0.3

2.58 ± 0.6

2.83 ± 0.0

Monocytes (Gr1int,F4/80int)

1.38 ± 0.0

1.38 ± 0.1

1.11 ± 0.0
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CHAPTER 3
Identification of Non-Covalent Binding Partners for ISG15
and Potential Functional Consequences
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Abstract
During Chikungunya virus (CHIKV) infection, ISG15 appears to play an immunoregulatory role
that is independent of UbE1L mediated conjugation. To understand mechanistically how free
ISG15 protects mice from infection, we characterized both intra- and extracellular unconjugated
ISG15 using mass spectrometry. By purifying serum ISG15 from pIC stimulated mice, we have
identified phosphorylation as a possible post translational modification of extracellular ISG15.
We have also identified the previously uncharacterized 30kDa serum ISG15 band as ISG15
conjugated to hemoglobin subunit beta-1. To identify non-covalent binding partners for
intracellular ISG15, we pulled down cytosolic proteins from BMM using a tagged ISG15
construct. Using this technique, we were able to identify over 140 unique potential binding
partners for free ISG15. To verify the ability of ISG15 to bind to our mass spec hits, we have
begun preliminary interaction studies and demonstrate that ISG15 co-ips with MDA5. As a start
to functional studies, we also demonstrate that free ISG15 can regulate cytokine production in
response to pIC stimulation. Further characterization of both intra- and extracellular ISG15 will
hopefully guide future experiments needed to determine ISG15s ability to regulate the host
response to viral infection.
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Introduction
Since the initial discovery of ubiquitin as a mechanism to target misfolded proteins to the
proteasome (1), this field has grown to include a multifaceted role for ubiquitin in a wide array of
cellular pathways. Ubiquitin’s activity is not limited to K48-conjugated chains, but includes a
variety of different linkages, activity for mono- and polyubiquitin, unanchored and conjugated
chains (2-7). In addition to its conjugation ability, ubiquitin also mediates non-covalent
interactions with proteins that contain Ubiquitin-binding domains(8, 9). We hypothesize that like
ubiquitin, ISG15 plays a multi-functional role that is dependent on both covalent modifications
and non-covalent interactions. How these interactions provide protection during viral infection is
largely unknown.
The mechanism by which ISG15 protects against viral infection is in-part dependent on
the type of invading pathogen. Based on our viral models, we have come up with two potential
non-mutually exclusive hypotheses on how ISG15 protects against virus infection. During
influenza B and Sindbis virus infection (10-12), ISG15 regulates viral loads, suggesting that
ISG15 can be directly antiviral. To date, this antiviral activity of ISG15 appears to be
conjugation dependent. During Chikungunya (13), influenza A and Sendai virus infections (Dave
Morales, unpublished), ISG15 does not regulate viral loads, suggesting an alternative mechanism
for ISG15. We hypothesize that ISG15 can also regulate the host response to viral infection and
dysregulation of the host response in ISG15-/- mice can lead to lethality. The regulation of host
response can either be conjugation dependent (influenza A and Sendai) or conjugation
independent (Chikungunya virus).
Our Chikungunya virus model provided a unique opportunity to go after a conjugation
independent mechanism for ISG15. Upon further investigation, we have also identified other
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alphaviruses where the role of ISG15 appears to be UbE1L independent, including neonatal Ross
River Virus and Barmah Forest Virus infections (Fig. S3.1). Based on our CHIKV model, we
hypothesized that ISG15 regulates the immune response to viral infection, as we observed
increased pro-inflammatory cytokine production in ISG15-/- despite similar viral loads as WT and
UbE1L-/- mice (13). Free ISG15 is found both intra- and extracellularly, therefore we have two
primary models by which free ISG15 could impact an immune response: (1) Extracellular free
ISG15 binds to an unidentified cell surface receptor which then modulates downstream cellular
signaling and/or (2) Intracellular free ISG15 binds non-covalently to intracellular molecules,
which then leads to altered cell signaling pathways. The key to addressing both of these potential
mechanisms is to identify the non-covalent binding partners for free ISG15.
Free ISG15 has been suggested to have cytokine like activity. Non-conjugated ISG15 can
be detected in the sera of humans treated with IFNβ as well as mice infected with certain viruses
(14). Recombinant ISG15 has been shown to increase NK cell proliferation and lytic activity
(15). Extracellular ISG15 has also been shown to act as a neutrophil chemoattractant and can
upregulate e-cadherin expression on dendritic cells (16, 17). Recently, recombinant ISG15 in
concert with IL-12 stimulation has been shown to upregulate IFNγ (18). The cytokine activity of
ISG15 may be biologically significant, as humans with null mutations for ISG15 display
Mendelian susceptibility to mycobacterial disease (MSMD), possibly due to lack of ISG15
mediated IFNγ production (18). Although ISG15 appears to have cytokine activity, a receptor for
ISG15 has not been identified.
Much less is known about the role of free ISG15 within a cell. During in vivo viral
infection, both free ISG15 and ISG15 conjugates can be detected in tissue homogenates (13, 19).
The over-expression of ISG15 has also been shown to disrupt Nedd4 ligase activity and inhibit
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Ebola virus VLP release, although it is unclear whether or not this activity is conjugation
dependent (20-22) . Recent research within the ubiquitin field has described a role for
unanchored polyubiquitin chains, shown to regulate TAK1 activation as well as RIG-I and
MDA5 signaling (23-25). Unanchored polyubiquitin chains generated by TRAF6 (23) or TRIM5
(26) bind to and activate the TAK1 complex, which influences downstream NF-κB signaling.
Unanchored polyubiquitin chains also bind to the CARD domains of RIG-I and MDA5, which
allows for oligomerization and optimal IRF3 activation (24, 25). Binding partners for free ISG15
within a cell is largely unknown.
The following describes our initial steps towards identifying mechanisms for both intra
and extracellular ISG15. Through mass spectrometry, we have identified phosphorylation as a
possible post-translational modification for serum ISG15. We have also identified the 30kDa
ISG15 band normally found in the serum of infected mice as ISG15 bound to hemoglobin
subunit beta-1. By generating recombinant tagged ISG15, we have identified over 140 potential
binding partners for intracellular ISG15 via mass spectrometry. Preliminary experiments have
been used to verify ISG15s ability to interact with the proteins identified from our mass spec
analysis and we demonstrate that ISG15 can co-immunoprecipitate with MDA5. Finally, we
demonstrate that free ISG15 can regulate cytokine production in response to pIC stimulation.
Our mass spec analysis of both extra- and intracellular ISG15 will aid future studies in
identifying a mechanism of action for free ISG15.
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Results

Serum ISG15 may be phosphorylated and the 30kDa ISG15 band is ISG15 conjugated to
hemoglobin subunit β-1.
Although ISG15 has been suggested to have cytokine like activity (15-17), a receptor for
ISG15 has not been identified. To complement ongoing studies for the ISG15 receptor, we
decided to characterize the natural secreted form of ISG15 to identify any post translational
modifications that may or may not be required for its binding/activity. In addition, we also hoped
to identify the previously unknown 30kDa ISG15 conjugate that is found in the serum of virally
infected WT mice (13).
To identify post translational modifications as well as the 30kDa ISG15 conjugate, we
purified serum ISG15 and sent isolated bands to the Yale MS & Proteomics facility. Adult WT
and ISG15-/- mice were injected with 50ug pIC ip, which is sufficient to induce serum ISG15
expression (data not shown). Serum was harvested on day 2 post treatment and ISG15 was
immunoprecipitated. Pulldown of ISG15 was confirmed by western blot analysis and bound
proteins were identified by SyproRuby stain (Fig. 3.1). Comparison of WT and ISG15-/- serum
allowed for identification of unique bands found only in WT serum, which were excised and sent
for mass spec analysis.
Gel bands were digested with trypsin and then analyzed via LC-MS/MS.
Phosphopeptides were enriched by passage over a titanium dioxide (TiO2) column. Results were
analyzed using the Swissprotein database and the confidence level was set to 95%. Two lower
molecular weight bands around 15kDa described as ISG15 lo and ISG15 hi were identified as
hemoglobin (alpha (15.1kDa) and beta-1 (15.8kDa) subunits) and ISG15, respectively. Two
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phosphorylated peptides were identified from the ISG15 band: a threonine at position 24 (Nterminal domain) and a tyrosine at position 139 (C-terminal domain) (Fig. 3.2 A and B) No other
modifications were found, with searches for methylation, acetylation, ubiquitination and
sumolyation. Phosphorylation of ISG15, either intra- or extracellular, has not been described and
will need to be verified.
Four higher molecular weight bands (between 30-40kDa) were sent for basic protein
identification, two from WT serum (W1 and W2) and the corresponding negative control bands
from ISG15-/- serum (S1 and S2).The 30kDa ISG15 conjugate (W2) was identified as ISG15
(MW=17.8kDa, 42% coverage) and hemoglobin subunit beta-1 (MW=15.8kDa, 59% coverage).
Neither of these proteins were identified in the corresponding ISG15-/- band S2. Numerous
unique proteins were identified for the W1 band, which based on our western blot analysis did
not appear to be an ISG15 conjugate. Based on the function of the identified proteins, we
hypothesized that the most likely candidate is the hemoglobin binding protein haptoglobin
(MW=38.7kDa, 5.5% coverage).
In an attempt to confirm that the ISG15 30kDa band is ISG15 conjugated to hemoglobin
subunit beta-1, we ran a western on CHIKV infected serum samples as well as our serum ISG15
pulldown and stained with an anti-hemoglobin antibody (Fig. 3.3). From our ISG15 pulldown,
we were able to detect the 30kDa band with the hemoglobin antibody. No 30kDa band was
detected in CHIKV infected serum, although we observed robust staining for free hemoglobin.
We hypothesize that only a small fraction of serum hemoglobin is modified, resulting in our
inability to detect the 30kDa band with the hemoglobin antibody in straight serum. A functional
role for the 30kDa serum ISG15 conjugate has not been described.
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Identification of Intracellular Binding Partners for Free ISG15 using Mass Spectrometry.
We hypothesized that free intracellular ISG15 could have activity within a cell,
independent of its ability to conjugate to target proteins, by binding non-covalently to other
intracellular proteins. Therefore, we generated recombinant ISG15 for immunoprecipitation
studies to identify potential binding partners by mass spectrometry.
ISG15 was cloned into a pfuse-hIgG1e3 Fc2 expression vector that includes a secretion
signal and a C-terminal mutant human Fc tag that is unable to bind to FcR. DIII (from WNV)
was also cloned to act as a negative control. Recombinant protein expression was confirmed by
western blot analysis (Fig. 3.4A). BMM, which produce many of the cytokines that were
elevated in our CHIKV model, were chosen as the target cell. Cytosol from IFN and pIC
stimulated ISG15-/- BMM was mixed with the recombinant protein and ISG15-Fc was
immunoprecipitated. Unique bands were identified by comparing ISG15-Fc and DIII-Fc
pulldowns and excised for basic protein identification by mass spec (Danforth facility) (Fig.
3.4B). Similar to our serum ISG15 pulldown, gel bands were trypsinized and analyzed using LCMS/MS. Data was searched against the NCBInr database.
Over 140 proteins were identified by mass spec analysis (after subtracting available
negative control hits) (Table 3.1). Proteins identified represent a variety of cellular pathways,
including innate immunity, vesicle sorting, cytoskeletal, ribosomal components and heat shock
proteins. Priority for studying potential hits was given by the following criteria: (1) interest (i.e.
innate immunity), (2) proteins that were also identified in Nadia’s Y2H screen (PCBP1 and
Clathrin, unpublished), (3) protein size matched the isolated protein band and (4) protein is not
found in the negative control band. Based on these criteria, the following proteins were identified
for initial follow up studies: MDA5, p62 (sequestosome-1), p40phox (NCF4), STAT1/2, and
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poly(C) binding protein 1 (PCBP1). Additional proteins found in Table 3.1 may share equal
potential for (1) binding to ISG15 and (2) important biological activity.

Human ISG15 co-precipitates with human MDA5
One of the proteins identified in our mass spec analysis was MDA5, a known
intracellular viral RNA sensor. MDA5, in combination with other viral sensors, has been shown
to play a role during CHIKV infection (27). Unanchored polyubiquitin chains have also been
shown to regulate MDA5 function (25). Therefore, we thought that MDA5 was a good
candidate for an ISG15 binding partner.
To confirm MDA5 as a binding partner for free ISG15, we over-expressed flag tagged
human MDA5 with either vector alone or with human or mouse ISG15 (without the conjugation
system) by transfecting 293T cells. Flag-MDA5 was immunoprecipitated and western blot
analysis was used to verify the pulldown (Flag) and check for the presence of free ISG15
(ISG15). Human ISG15 can be pulled down by anti-Flag human MDA5 immunoprecipitation
(Lane 2- Fig. 3.5). Interestingly, mouse ISG15 did not co-ip with human MDA5 (Lane 3), which
may suggest a species specific interaction. We also attempted pulldowns with two truncated
forms of human MDA5 that were obtained from Michael Gale’s lab: MDA5 1-294 (CARD
domains) and MDA5 295-1025 (RNA helicase domain) (Lanes 4-7)(28). Human ISG15 could be
pulled down by both of these constructs (Lanes 5 & 7), although there appeared to be more
ISG15 with MDA5 1-294. We also attempted to pulldown ISG15 with Flag human RIG-I, which
was not identified in our mass spec analysis. We saw only a weak band for human ISG15,
suggesting weak or no binding, and no bands for mouse ISG15 (Lanes 8-9). Therefore, human
ISG15 co-precipitates with human MDA5 but not RIG-I. Preliminary data also suggests that
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ISG15 may co-ip with additional binding partners identified via mass spec, including STAT1,
p62 and p40phox (NCF4).

ISG15-/- mice and cells have increased IL-6 production in response to pIC stimulation.
If we are able to confirm MDA5 as a binding partner for free ISG15, it will be important
to determine if there is a functional consequence for this interaction. The best approach will be to
stimulate MDA5 in the presence or absence of ISG15. MDA5 has been shown to be responsible
for cytokine production (IFNα, TNFα, MCP-1, IL-6) in response to naked pIC and complexed
pIC (transfection) (29). Cytokine production following pIC stimulation is primarily MDA5
dependent, althoughTLR3 can also produce these cytokines in response to pIC (29). We
hypothesized that ISG15 regulates cytokine production downstream of MDA5 signaling.
Therefore, we investigated the ability of ISG15 to regulate cytokine production in response to
pIC.
In order to address whether ISG15 could directly affect cytokine production, we
developed an in vitro model to examine ISG15s impact on pIC stimulation. Primary cells (BMM,
BMDC, and muscle fibroblasts) were generated from WT, UbE1L-/- and ISG15-/- mice. Cells
were pretreated with IFNβ to induce ISG15 (data not shown). 24hrs post IFNβ treatment, cells
were then stimulated with pIC (10ug/mL). Cell supernatants were harvested at 4,12 and 24hrs
post pIC stimulation. Cytokine production (TNFα, IL-1β, IL-6, IL-10, and various chemokines)
were assessed by bioplex.
Production of IL-6 following pIC stimulation appeared to replicate our in vivo CHIKV
results: WT and UBE1L-/- cells produce similar levels of IL-6, whereas ISG15-/- cells have
increased IL-6 production (at best 2-fold) at 12 and 24hrs post stimulation. This phenotype was
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found for BMM (Fig. 3.6A) and primary muscle fibroblasts (Fig. 3.6B). Preliminary data
suggests that this same trend was also observed in BMDC, although IL-6 production was much
lower than BMM and muscle cells (data not shown). Therefore, under these conditions, free
ISG15 appears to act as a negative regulator of IL-6 production following pIC stimulation.
To complement our in vitro findings, we also developed an in vivo model for pIC
stimulation. Nine day old WT, UbE1L-/-, and ISG15-/- mice were injected with pIC (10ug) s.c.
and serum was harvested at 6 and 24hrs post treatment. ISG15 could be found in the serum of
pIC stimulated WT and UbE1L-/- mice at both 6 and 24hrs post stimulation (data not shown).
Similar to our in vitro findings, ISG15-/- mice display elevated levels of IL-6 production at 6hrs
post treatment compared to WT and UbE1L-/- mice (Fig. 3.6C). This data suggests that free
ISG15 regulates IL-6 production following pIC stimulation.
Similar to IL-6, production of IL-10 following pIC stimulation in BMM appeared to
replicate our in vivo CHIKV phenotype (Table 3.2). ISG15-/- BMM pretreated with pIC
produced more IL-10 (at best 2-fold) than WT and UbE1L-/- BMM 12 and 24hrs post
stimulation. As IL-6 is a known regulator of IL-10 (30), it is unclear as to whether this phenotype
is due to ISG15s ability to directly regulate the IL-10 pathway or simply due to increased levels
of IL-6. BMDCs and primary muscle fibroblasts did not produce IL-10 in response to pIC
stimulation, suggesting that unlike IL-6, this phenotype is cell type dependent.
The other analytes that we evaluated did not show the same trend as IL-6 and IL-10
production (Table 3.2). WT BMM display increased TNFα production compared to UbE1L-/- and
ISG15-/- BMM 4hrs after pIC stimulation. In addition, IL-1β production was not detected and no
difference was observed for chemokine levels (MIP-1α, MCP-1 and GM-CSF). In addition,
ISG15 mediated regulation appears to be cell type dependent, as different cells produced
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different cytokine patterns in response to pIC stimulation. Interestingly, changing the type of
TLR stimulation, including LPS (TLR4) or Imiquimod+ATP (inflammasome activation) also
produced a different pattern of ISG15 mediated cytokine regulation (Figure S3.2 and Table 3.2).
Preliminary data suggests that IL-6 production following LPS stimulation in vitro (Fig. S3.2A)
or in vivo (Fig. S3.2B) is positively regulated by ISG15 conjugation. Following inflammasome
activation, production of IL-1β appears to be negatively regulated by ISG15 conjugation (Table
3.2)Therefore, free ISG15 does not act as a master regulator for cytokine production and
regulation may be dependent on select cytokine signaling pathways, the type of cell as well as
the type of stimulation.
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Discussion
Free extracellular ISG15 has been described to have cytokine activity, although how
ISG15 mediates this activity is unknown (15-17). Even less has been reported for the activity of
free intracellular ISG15 (20-22). However, our CHIKV model, as well as recent reports that
confirm earlier cytokine studies (18), suggest that free ISG15 has an important role in the
immune response to both viral and bacterial pathogens. To setup future mechanistic studies, we
have characterized both free forms of ISG15, intra- and extracellular, using mass spectrometry.
Our results show that serum ISG15 may be modified by phosphorylation, which may or may not
be necessary for ISG15 function. In addition, we identify the 30kDa ISG15 conjugate commonly
found in virally infected WT mice as ISG15 conjugated to hemoglobin subunit beta-1. For
intracellular ISG15, we have identified 146 potential binding partners that are involved in
multiple cellular pathways. Preliminary co-ip data confirms that at least some of these hits may
be valid, as ISG15 can co-ip with MDA5. We also demonstrate that ISG15 can regulate cytokine
production in response to pIC stimulation, although it is unclear if this is dependent on ISG15s
interaction with MDA5.
Recombinant ISG15 has been shown to regulate innate immune cell responses, affecting
the activity of monocytes, neutrophils and NK cells. To fully understand how extracellular
ISG15 mediates its activity, a receptor for serum ISG15 must be identified. As a requisite step in
identifying an ISG15 receptor, we have identified phosphorylation as a potential posttranslational modification of 15kDa serum ISG15 (Fig. 3.1 and 3.2). Interestingly, we identified
two phosphopeptides for ISG15, each corresponding to one of the two ubiquitin domains of
ISG15: Thr24 N-terminus and Y139 C-terminus. Mutagenesis of these two sites will help confirm
whether ISG15 is phosphorylated and may aid in future functional studies. The consequences of
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ISG15 phosphorylation are unknown. It is unclear if phosphorylation affects the secretion or
activity of ISG15, if intracellular ISG15 is also modified, and what percentage of total ISG15
gets modified. Generation of recombinant ISG15 in the literature was not described as being
phosphorylated and yet activity was still reported, so it is unclear if phosphorylation will affect
the activity of secreted ISG15.
We have also identified the 30kDa serum ISG15 conjugate as ISG15 bound to
hemoglobin subunit beta-1 (Fig. 3.1 and 3.3). To our knowledge, the role of the 30kDa conjugate
has not been investigated and its function is unknown. Its role outside of the cell may have an
important biological function or it may be a byproduct of red blood cell lysis. Intracellular
ISGylated hemoglobin may also have an important function that remains to be investigated.
Although hemoglobin expression is predominantly found in red blood cells, it can also be
expressed in additional cell types, including alveolar cell lines, activated macrophages from adult
mice and embryonic neurons (31-33). We hypothesize that identification of hemoglobin as the
ISG15 lo band may result from degradation of the 30kDa ISG15 band or may result from noncovalent association with the ISG15 or hemoglobin portion of the 30kDa band. Indeed, it is
known that hemoglobin beta and alpha subunits form a tetramer complex. We suspect that the
unique higher molecular weight band W1 is likely haptoglobin. Haptoglobin, which binds to and
sequesters serum hemoglobin, may be coming down in our ISG15 ip due to its interaction with
the hemoglobin subunit beta (34). However, this also remains to be verified. Identification of the
ISGylated hemoglobin subunit beta-1 residue (via mass spec (diglycine shift) or Lysine
mutagenesis) may aid in the discovery of a functional role for the 30kDa ISG15 conjugate.
Most importantly, we have shown that free ISG15 has the capacity to bind to many
different intracellular proteins, independent of its conjugation activity (Fig. 3.4). Most of these
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potential binding targets remain to be verified and may be either direct or indirect ISG15 binding
partners. We recognize that ISG15 may be binding to only a select few of these potential targets
and a large number of hits that we have generated may result from the formation of protein
complexes that are not dependent on direct ISG15 binding. Nonetheless, these mass spectrometry
hits will allow us to focus on different cellular pathways that free ISG15 may be involved in,
including innate immune signaling and vesicle sorting pathways. Our mass spec hits are specific
for IFN/pIC stimulated BMM, therefore may not represent additional binding partners in
different cells or in response to other forms of stimulation (TLR4, inflammasome, etc).
The results that we have generated from our non-covalent pulldown have directed our
attention to cellular pathways that ISG15 may be involved in. We note that ISG15 associates
with several ribosomal components and proteins associated with protein translation. We
hypothesize that this association may be linked to the conjugation activity of Herc5, the main E3
ligase for ISG15 that also associates with ribosomal subunits (35). Several proteins involved in
vesicular transport were also identified, including the retrograde transport proteins SNX1 and
SNX2. As ISG15 lacks a signal peptide necessary for classical protein secretion, we hypothesize
that ISG15s ability to interact with vesicular proteins may lead to discovery of the secretion
mechanism for ISG15. Alternatively, ISG15s ability to interact with the vesicular transport
pathway may be a way to regulate cell responsiveness by retrograde transport of cell surface
receptors (36) or may reflect previously reported data where ISG15 impacts VLP release via the
ESCRT pathway (22). Perhaps unexpectedly, we also identified several proteasome regulatory
subunits, as a role for ISG15 in proteasome mediated degradation has not been described. Lastly,
as ISG15 plays a vital role during viral infection, we hypothesize that the proteins that we have
identified as innate immune proteins may represent important binding interactions for ISG15.
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Indeed, we have identified the PRRs MDA5, LGP2, and DAI as well as additional proteins
known to play a role in cytokine production, such as FLN29 and BCAP1 (37, 38). In Chapter 4,
we briefly discuss the importance of some of the proteins that we have identified for use in future
functional studies.
In an attempt to verify targets of our intracellular ISG15 analysis, we demonstrate that
ISG15 co-ips with MDA5 (Fig. 3.5). The ability of ISG15 to directly bind MDA5 has not been
demonstrated and will require further study. MDA5 is an exciting potential target for ISG15 as it
is a known sensor for CHIKV, plays a role in cytokine production, and is also known to be
regulated by unanchored ubiquitin chains (25, 27, 39). Unanchored polyubiquitin chains bind to
the Card domains of both MDA5 and RIG-I, which allows for oligomerization and full activation
of downstream signaling (25). One hypothesis that could explain our observations is that free
ISG15 disrupts the binding of unanchored ubiquitin chains to MDA5, resulting in downregulation of this signaling pathway. Therefore, when ISG15 is absent, the MDA5 signaling
pathway will remain active, resulting in increased cytokine production observed in ISG15-/-.
Interestingly, RIG-I was not identified in our mass spec analysis and ISG15 did not co-ip with
RIG-I in our overexpression studies, suggesting that ISG15s ability to co-ip with MDA5 may
result from a specific interaction.
In an attempt to show that there is a functional consequence for ISG15s interaction with
MDA5, we also stimulated cells and mice with the MDA5/TLR3 agonist pIC (29). We were
encouraged to find that IL-6 production following pIC stimulation in vitro and in vivo gave
similar results to our CHIKV model (Fig. 3.6). Preliminary data generated by infecting primary
muscle fibroblasts with CHIKV suggested that IL-6 production did mirror our in vivo findings,
although the levels of IL-6 produced were significantly lower than following pIC stimulation
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(data not shown). We hypothesize that this may be due to CHIKVs ability to interfere with
transcription and translation (40). Although we were able to demonstrate a role for ISG15 in
cytokine production, we were unable to generate an in vitro model that completely replicates our
in vivo CHIKV phenotype. This may be due to our inability to generate the complex cellular and
tissue interactions found in vivo or due to using pIC stimulation instead of CHIKV infection.
We hypothesize that ISG15 may regulate MDA5 mediated signaling, however, we cannot
rule out a contribution of TLR3 in our pIC stimulation studies. We also cannot explain why only
some and not all cytokines appear to be regulated by free ISG15. If our hypothesis that ISG15
can directly regulate PRR signaling was correct, we would hypothesize that more cytokines
would be dependent on free ISG15 (which we observe from our in vivo model but not in vitro).
An alternative hypothesis may be that ISG15 regulates PRR cytokine production farther
downstream of the initial PRR signaling pathway, which could allow for individual cytokine
regulation.
In summary, we have begun preliminary functional studies to identify a mechanism of
action for free ISG15. We have characterized the natural secreted forms of ISG15, identifying
phosphorylation as a potential post translational modification and identifying the 30kDa
conjugate as ISG15 bound to hemoglobin subunit beta-1. We have also identified many different
potential binding partners for free intracellular ISG15 and have verified ISG15s ability to co-ip
with MDA5. We demonstrate that ISG15 regulates cytokine production following PRR
activation and show that ISG15-/- have elevated IL-6 levels following pIC stimulation. Free
ISG15s ability to form non-covalent interactions with other proteins represents an exciting
opportunity to identify a conjugation independent mechanism for ISG15.
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Materials and Methods

Mice
Mouse studies were performed at Washington University in St. Louis in accordance with
the recommendations in the Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health and following the International Guiding Principles for Biomedical Research
Involving Animals. The protocols were approved by the Animal Studies Committee at
Washington University (#20090287). The generation of both the ISG15-/- and UbE1L-/- mice has
been previously described (41, 42). Congenic SNP analysis (Taconic laboratories) of UbE1L-/and ISG15-/- mice confirmed that these mice were fully backcrossed, with 99.93% and 99.72%
identity to C57BL/6 mice, respectively. For serum ISG15, adult 6-8week old WT and ISG15-/mice were injected with 50ug pIC i.p. and serum was harvested 48hrs post-treatment. For in vivo
pIC stimulation, 9 day old WT, UbE1L-/- and ISG15-/- pups were injected with 10ug pIC s.c.

Purification of Serum ISG15
Serum from pIC treated WT and ISG15-/- adult mice was incubated with monoclonal 3C2
anti ISG15 coupled beads, washed with PBS and eluted using a glycine buffer (0.1M, pH 2.5).
Pulldown of ISG15 was confirmed using western blot analysis by running proteins on a 12% Tris
gel, transferring to a polyvinylidene fluoride membrane, and blotting with a rabbit anti-ISG15
polyclonal serum (1:5000) as previously described (19). Bound proteins were run on a precast
12% Tris gel and identified using SyproRuby stain. Unique bands were excised and sent for
identification of post-translational modifications and basic protein identification by mass
spectrometry.

113

Generation of tagged ISG15 for Non-covalent pulldowns
Mouse ISG15 and the WNV domain DIII were cloned into the expression vector pfusehIgG1e3 Fc2 (invivogen), which includes a signal peptide for secretion and a C-terminal Fc tag.
Generation of Fc tagged constructs was confirmed by transfecting 293T cells using
Lipofectamine and harvesting supernatant and cell lysate 48hrs post transfection. Proteins were
run on a 12% Tris gel and transferred to a polyvinylidene fluoride membrane for western blot
analysis. Anti-human Fc (Goat anti-human Fc-HRP: Jackson Immunoresearch 109-035-098) was
used for detection. The membrane was incubated in 5-10% milk 1:15000 antibody dilution for 12hrs,washed 4x with PBS-Tween and resolved with Chemiluminescent HRP substrate (Millipore
Immobilon Western: WBKLS0500).
Mass production of Fc-tagged proteins was performed by transfecting 293 suspension
cells (293F cells) provided by Dr. Daved Fremont. Cells were grown in serum free media (Gibco
FreeStyle 293 media; cat no: 12338-018) at 37C, 8% CO2 in a ThermoScientific 500mL flask
(4115-0500 PETG flask with vented closure). Cells were seeded at 0.5x106 cells/mL in 100mL
the day before transfection of the Fc constructs using PEI (1ug DNA/mL). Supernatant was
harvested every three days. Fc constructs were purified from supernatant using Protein A beads
and dialyzed against PBS using Slide-A-Lyzer Dialysis Cassettes (ThermoScientific).
Purification was confirmed using western blot analysis described above and SyproRuby staining.
For identification of binding partners, purified Fc constructs was mixed with cytosol from
bone marrow macrophages (BMM). Generation of BMM is previously described. ISG15-/- BMM
were lysed with digitonin buffer and the cytosol enriched fraction was incubated with the Fc
constructs overnight. Fc proteins along with binding partners were purified using Protein A
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beads. Bound proteins were run on a precast 12% Tris gel and identified using SyproRuby stain.
Unique bands were excised and sent for protein identification by mass spectrometry.

Mass Spectrometry
Unique bands for the serum ISG15 pulldown were sent to the MS & Proteomics WM
Keck Foundation Biotechnology Resource Laboratory at Yale University. Analysis was led by
Dr. Kathryn Stone and Jean Kanyo. Gel bands were digested with trypsin and then peptides were
separated on a Waters nanoACQUITY (75 µm x 250 mm eluted at 300nl/min.) with MS analysis
on a LTQ Orbitrap mass spectrometer. ISG15 lo and hi gel bands were also passed over a
titanium dioxide column to enrich for phosphopeptides. The LC-MS/MS results were searched
using the SwissProt database. Mascot distiller and the Mascot search algorithm were used for
database searches. Unique bands for the Fc-ISG15 pulldown were sent to the Donald Danforth
Plant Science Center Proteomics and Mass Spectrometry Facility in St. Louis with analysis by
Dr. Sophie Alvarez. As described above, gel bands were digested with trypsin for LC-MS/MS
analysis. Confidence level for all hits was set at 95%.

Co-immunoprecipitations
293T cells were transfected (Lipofectamine) with human or mouse ISG15 alone or in
combination with Flag tagged target constructs. Human MDA5 and RIG-I constructs were
obtained from Dr. Michael Gale’s lab and are previously described (28). 24hrs post transfection,
cells were lysed with digitonin and cell lysate was incubated with anti-Flag beads. Pulldown of
Flag and/or ISG15 constructs was confirmed via western blot analysis, as described above. AntiFlag and rabbit anti-ISG15 polyclonal sera was used for protein detection.
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TLR Stimulation and Cytokine Analysis
For in vitro stimulation, primary bone marrow derived macrophages, bone marrow
derived dendritic cells and primary muscle fibroblasts were generated. Cells were pretreated with
10U/mL IFNβ. 24hrs post IFN treatment, cells were stimulated with pIC (10ug/mL), LPS
(10ng/mL) or imiquimod pulsed with ATP (43). Cell supernatants were harvested at 4, 12, and
24hrs post treatment. For in vivo stimulation, 9 day old mice were treated with pIC (10ug) s.c.
and serum was harvested 6 and 24hrs post stimulation. Cytokines were measured using Luminex
technology with a customized 6plex from Biorad.
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Figure 3.1. Mass spectrometry analysis of serum ISG15 indicates that free ISG15 (ISG15
Hi) may be phosphorylated and the 30kDa band (W2) is ISG15 conjugated to hemoglobin
subunit beta-1. WT and ISG15-/- adult mice were injected with 50ug pIC i.p. and serum was
harvested on day 2 post treatment. Serum ISG15 was pulled down with aISG15 coupled beads
(mouse monoclonal). (A) Western blot was used to confirm pulldown of ISG15 (rabbit
polyclonal). (B) ISG15 and associated bands were identified by Syproruby stain. Bands sent off
for mass spec (Yale) are highlighted in red.
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Figure 3.1
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Figure 3.2. Thr24 and Tyr139 were identified as potential phosphorylation sites for serum
ISG15. WT and ISG15-/- adult mice were injected with 50ug pIC i.p. and serum was harvested
on day 2 post treatment. Serum ISG15 was pulled down with aISG15 coupled beads (mouse
monoclonal). Purified protein was digested with trypsin and phosphopeptides were enriched
using a TiO2 column for mass spec analysis at the Yale MS & Proteomics facility.
Phosphorylated residues (red) from their respective peptides (black) are represented in the
context of the mouse ISG15 amino acid sequence (processed)(grey).
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Figure 3.2

MAWDLKVKMLGGNDFLVSVTNSMTVSELKKQIAQ
KIGVPAFQQRLAHQTAVLQDGLTLSSLGLGPSSTVM
LVVQNCSEPLSILVRNERGHSNIYEVFLTQTVDTLKK
KVSQREQVHEDQFWLSFEGRPMEDKELLGEYGL
KPQCTVIKHLRLRGG
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Figure 3.3. The 30kDa ISG15 band appears to be ISG15 conjugated to hemoglobin subunit
beta-1 (preliminary data). (A) Serum ISG15 from pIC stimulated adult mice was pulled down
with aISG15 coupled beads and blotted for aISG15 and αHemoglobin β (αHgbβ) (B) Nine day
old WT, UbE1L-/- and ISG15-/- neonates were infected with CHIKV (105pfu s.c.). Serum was
harvested on day 2 post infection and blotted for aISG15 and αHgbβ.
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Figure 3.4. Generation of recombinant ISG15-Fc and identification of non-covalent binding
partners. ISG15 and DIII (WNV) were cloned into an expression vector that includes a
secretion signal and a C-terminal mutated human Fc tag that is unable to bind to FcR. 293S cells
were transfected and Fc tagged proteins were purified from supernatant with Protein A beads.
Bound Fc proteins were eluted with glycine, collected in Tris and dialyzed in PBS. (A) Anti-Fc
western blot was used to confirm the presence of both proteins after the purification process. The
lower MW band in the ISG15-Fc fraction appears to be a cleaved Fc contaminant. (B) Purified
proteins were then mixed with cytosol from IFNβ/pIC stimulated ISG15-/- BMM. ISG15-Fc was
pulled down with Protein A beads along with bound proteins. Unique bands were sent for mass
spec protein id (Danforth). Excised bands are indicated on the right insert (ISG15-Fc bands in
blue, control bands in green).
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Figure 3.5. Human ISG15 interacts with human MDA5 by co-ip. Flag tagged hMDA5 (or
hRIG-I) was coexpressed with untagged hISG15 (1:1 ratio) in 293T cells. Cells were lysed with
Digitonin and Flag proteins were immunoprecipitated. Western blot was used to confirm protein
expression in bound (A) and unbound (B) fractions.
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Figure 3.6. ISG15-/- cells and mice produce more IL-6 than both WT and UbE1L-/following pIC stimulation. Bone marrow macrophages (BMM) (A) and primary muscle
fibroblasts (B) were pretreated with IFNb for 24hrs and then stimulated with pIC (10ug/mL). (C)
WT, UbE1L-/- and ISG15-/- mice were injected with 10ug pIC s.c. (A-C) Supernatant and serum
was harvested at the indicated timepoints and IL-6 levels were measured by bioplex.
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Figure S3.1. ISG15, independent of UbE1L, plays a critical role during the neonatal
response to certain alphavirus infections. WT, UbE1L-/- and ISG15-/-mice were infected with
(A) 103pfu RRV s.c. at 14 days of age, (B) 105pfu VEEV TC-83 s.c. at 9 days of age, (C) 106pfu
Barmah Forest Virus s.c. at 9 days of age, (D) 105pfu Bebaru s.c. at 9 days of age. Mice were
monitored for lethality for 21 days with data displayed as Kaplan-Meier curves. Similar survival
for Bebaru was observed at 100pfu. No lethality was observed in adult ISG15-/- mice infected
with TC-83 (104pfu i.c.) or Bebaru (106pfu s.c.).
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Figure S3.1
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Figure S3.2. ISG15-/- and UbE1L-/- mice and cells produce less IL-6 in response to LPS
compared to WT mice/cells (preliminary data). (A) WT, UbE1L-/- and ISG15-/- BMM were
pretreated with 10U IFNb 24hrs before stimulation with LPS. Supernatants were collected at 4
and 12hrs post LPS treatment. IL-6 levels were measured by bioplex. (B) Nine day old WT and
ISG15-/- mice were treated with LPS i.p. and serum was harvested 6 and 24hrs post treatment.
IL-6 levels were measured by bioplex.
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Table 3.1 Potential Non-Covalent Binding partners for free ISG15 identified via mass spec
(ISG15-Fc pulldown with IFN/pIC stimulated ISG15-/- BMM).
Biological Process
Signaling

Innate Immunity

NCBI Accession
Number
13959396
148668602
114326482

Gene Name

Protein Name

Iqgap1
Ap3bp1
Stat1

13633965

Stat2

187471159
170172575

Hmha1
Inppl1

148701340
168983832
46559406
124517663
157951604
13096922
13878195
11528490
123701966

Fermt3
Anxa2
Pak2
Anxa1
Cap1
Arhgap17
Pik3ap1
Flii
Kctd12

24025665

Plekho2

123241346
1209068

Sh3bp1
Inpp5d

15489209
123227481
124248570

Themis2
Ybx1
G3bp2

225543183

Vwa5a

20138411
1915913
192657

Ptk2b
Dpysl2
Ppp3ca

255003810

Rab3gap2

37590218

Abr

45597447
40675709
309255

Sod1
Syk
Gnai2

19852058

Dscaml1

6644338
6754954

Prdx5
Sqstm1

Ras GTPase-activating-like protein IQGAP1
AP-3 complex subunit beta-1
Signal transducer and activator of
transcription 1
Signal transducer and activator of
transcription 2
Minor histocompatibility protein HA-1
Phosphatidylinositol 3,4,5-trisphosphate 5phosphatase 2
Fermitin family homolog 3
Annexin A2
Serine/threonine-protein kinase PAK 2
Annexin A1
Adenylyl cyclase-associated protein 1
Rho GTPase-activating protein 17
Phosphoinositide 3-kinase adapter protein 1
Protein flightless-1 homolog
BTB/POZ domain-containing protein
KCTD12
Pleckstrin homology domain-containing
family O member 2
SH3 domain-binding protein 1
Phosphatidylinositol 3,4,5-trisphosphate 5phosphatase 1 (Ship1)
THEMIS2 (Icb1)
Y box protein 1
GTPase activating protein (SH3 domain)
binding protein 2
von Willebrand factor A domain-containing
protein 5A (Loh11cr2a)
Protein-tyrosine kinase 2-beta
Dihydropyrimidinase-related protein 2
Serine/threonine-protein phosphatase 2B
catalytic subunit alpha isoform
Rab3 GTPase-activating protein noncatalytic subunit
Active breakpoint cluster region-related
protein
Superoxide dismutase [Cu-Zn]
Tyrosine-protein kinase (Syk)
Guanine nucleotide-binding protein G(i)
subunit alpha-2
Down syndrome cell adhesion molecule-like
protein
Peroxiredoxin-5
Sequestosome 1 (p62)
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#U
pep
15
6
7
8
6
7
7
6
4
4
3
2
3
4
4
4
3
3
2
2
2
3
3
3
2
2
2
2
2
2
2
2
6

Vesicle Transport/
Phagocytosis

Protein Translation

91064876
132252411

Gbp5
Ifih1

160333495
213418055

Gm14446
Samhd1

15030162

Gbp2

51702775

PPIA

115270958
70608133

Gvin1
Dhx58

14861844
15489209
23468336

D1Pas1
Themis2
Trafd1

6754994
18044838
26326901

Pcbp1
Zbp1
Ripk1

1698556
287323109
114326482

Ncf4
Hck
Stat1

13633965

Stat2

15341745

Ehd4

13385878
31543349
12248793
51491845
227116320
83649760
22122347

Snx2
Nsf
Snx1
Cltc
Fkbp15
Wash1
Gga1

23956096
22477515
26354649
13278382
12963511
200796
3097244
6677775
1083569
116517301
127798883
127799069

Uso1
Ehd1
Pabp1
Eef1a1
Rps19
Rps16
Rps14
Rpl22
Hnrnpk
Ptbp1
Cyfip1
Syncrip

9506571

Eif2s1
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Guanylate binding protein 5
Melanoma differentiation-associated protein
5 (MDA5)
Gm14446 protein
SAM domain and HD domain-containing
protein 1 (Mg11)
Interferon-induced guanylate-binding protein
2
Peptidyl-prolyl cis-trans isomerase A
(Cyclophilin A)
Interferon-induced very large GTPase 1
Probable ATP-dependent RNA helicase
DHX58 (LGP2)
Putative ATP-dependent RNA helicase Pl10
THEMIS2 (Icb1)
FLN29 (TRAF-type zinc finger domaincontaining protein 1)
poly(rC)-binding protein 1
Z-DNA-binding protein 1
Receptor-interacting serine/threonine-protein
kinase 1
Neutrophil cytosol factor 4 (p40phox)
Tyrosine-protein kinase HCK
Signal transducer and activator of
transcription 1
Signal transducer and activator of
transcription 2
EH-domain containing 4

7
7

Sorting nexin 2
Vesicle-fusing ATPase
Sorting nexin 1
Clathrin heavy chain 1
FK506-binding protein 15
WAS protein family homolog 1
ADP-ribosylation factor-binding protein
GGA1
General vesicular transport factor p115
EH-domain containing 1
Polyadenylate binding protein 1
Elongation factor 1-alpha1
40S ribosomal protein S19
40S ribosomal protein S16
Ribosomal protein S14
60S ribosomal protein L22
Heterogeneous nuclear ribonucleoprotein K
Polypyrimidine tract binding protein 1
Cytoplasmic FMR1-interacting protein 1
Heterogeneous nuclear ribonucleoprotein Q
(hnRNP Q)
Eukaryotic translation initiation factor 2
subunit 1

11
8
7
3
4
3
2

8
5
6
4
2
4
4
2
3
3
2
2
2
2
7
8
15

2
2
13
8
9
10
7
5
6
2
4
4
4

Cytoskeletal

Ubiquitin/UBL

Protein Folding/
Stress Response

118344452
11527388
13905140
118600514
123235430
61743961
114326446
227116327
125347376
7106439
33620739
134288917
148747189
47124599
149263685
127798883
118136288
255069756
123207565
110625624
161086971
6756085
148708988
22122795

Srp72
Qki
Farsa
Fam129a
Srp14
Ahnak
Myh9
Tln1
Flna
Tubb5
Myl6
Dync1h1
Map4
Diap1
Ahnak2
Cyfip1
Fmnl1
Myo1f
Dync1i2
Tcp1
Capza1
Zyx
Dsp
Dync1li1

21594742
125987599
7710044
237820660
127139140
123264882
116283726
6679501
15823094

Elmo1
Cd2ap
Keap1
Ubr4
Trim21
Rnf213
Psmd1
Psmc1
Ubl4

31980712
4507793
257153392

Usp25
UBE2N
Ufd1l

6754724

Psmd7

5031981

Psmd14

19705424

Psmd3

5353754
118490060

Ddb1
Hspa1a

118142832
126723461
62948125

Hsp90aa
Cct8
Cct6a
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Srp72
Protein quaking
Phenylalanine--tRNA ligase alpha subunit
Niban
Srp14
AHNAK nucleoprotein isoform 1
Myosin-9
Talin 1
Filamin A
Tubulin beta-5 chain
Myosin light polypeptide 6
Cytoplasmic dynein 1 heavy chain
Microtubule-associated protein 4
Diap1 protein
AHNAK2
Cytoplasmic FMR1-interacting protein 1
Formin-like protein 1
Myosin IF
Dynein cytoplasmic 1 intermediate chain 2
T-complex protein 1 subunit alpha
F-actin-capping protein subunit alpha-1
Zyxin
Desmoplakin
Dynein cytoplasmic 1 light intermediate
chain 1
Engulfment and cell motility protein 1
CD2-associated protein
Kelch-like ECH-associated protein 1
E3 ubiquitin-protein ligase UBR4
E3 ubiquitin-protein ligase TRIM21
Ring finger protein 213
Psmd1 protein
26S protease regulatory subunit 4
Housekeeping protein DXS254E

2
3
3
2
2
37
28
7
12
4
8
12
4
5
2
4
3
3
3
3
2
2
2
2

Ubiquitin carboxyl-terminal hydrolase 25
ubiquitin-conjugating enzyme E2 N
Ubiquitin fusion degradation protein 1
homolog
26S proteasome non-ATPase regulatory
subunit 7
26S proteasome non-ATPase regulatory
subunit 14
26S proteasome non-ATPase regulatory
subunit 3
DNA damage-binding protein 1
Inducible heat shock protein 70

2
3
3

Hsp90aa protein
T-complex protein 1 subunit theta
Chaperonin containing Tcp1, subunit 6a
(Zeta)

6
3
3

2
2
9
12
5
6
5
4
4

2
2
2
2
8

Metabolism

Other

110625624
238814391
5353754
1674501
1405933
109734501
19527028

Tcp1
Cct7
Ddb1
Anpep
Pkm
Hk3
Hdlbp

13529599
110590524
14250204
26347093
52353955
7242171
27371140
15079335

Ldha
Nampt
Mthfd1
Pfkp
Phgdh
Pcna
Bag6
Snrpd3

Resources: NCBI protein: http://www.ncbi.nlm.nih.gov
UniProtKB: http://www.uniprot.org/uniprot
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T-complex protein 1 subunit alpha
Chaperonin subunit 7 (Eta), isoform CRA_a
DNA damage-binding protein 1
Aminopeptidase N
Pyruvate kinase isozymes M1/M2
Hk3 protein (hexokinase 3)
High density lipoprotein-binding protein
(Vigilin)
L-lactate dehydrogenase
Nicotinamide phosphoribosyltransferase
C-1-tetrahydrofolate synthase, cytoplasmic
6-phosphofructokinase type C
D-3-phosphoglycerate dehydrogenase
Proliferating cell nuclear antigen
Bat3 protein
Small nuclear ribonucleoprotein D3

3
2
2
3
5
2
4
3
2
2
2
2
2
2
2

Table 3.2. Regulation of BMM cytokine production by ISG15 in response to TLR
stimulation. (negative or positive regulation, free or conjugation dependent)
TLR Stimulation

IL-6

IL-10

TNFα

IL-1β

chemokine

pIC

neg/Free

neg/Free

pos/Conj

n.d.

No diff

LPS

pos/Conj

neg/Conj

No diff

No diff

No diff

Imiq+ATP

n.d.

n.d.

n.d.

neg/Conj

n.d.
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CHAPTER 4
Summary and Future Directions

The following chapter contains an excerpt from the following publication:
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Levine, O. Schwartz, D. J. Lenschow, and M. L. Albert. 2012. Chikungunya virus-induced
autophagy delays caspase-dependent cell death. J Exp Med 209:1029-1047.
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Summary
Although Chikungunya Virus was first described in 1952, very little was known about
CHIKV until recently, due to increased attention brought about by the 2005 La Reunion outbreak
(1, 2). During this outbreak, in addition to the classical symptoms of rash, joint pain and fever,
novel symptoms were also reported, with increased severity in infants, elderly and the immune
compromised (3-6). As the CHIKV epidemic grew, scientists recognized the need to learn more
about the life cycle and host response to CHIKV, in the hopes of alleviating or preventing future
CHIKV outbreaks. Our collaborators at the Pasteur Institute successfully developed a mouse
model for CHIKV, allowing for initial studies on CHKV pathogenesis (7). As with other viruses,
type I interferons (IFN) were shown to be vital for the control of CHIKV infection (7, 8). Type I
IFN mediates antiviral protection through the upregulation of hundreds of IFN stimulated genes
(ISGs) (9). However, the role of ISGs during CHIKV infection was largely unknown. In this
thesis, we focused our efforts on learning more about CHIKV pathogenesis, in part by describing
a role for the interferon stimulated gene ISG15.
Due to increased severity of disease symptoms in infants, we focused our attention on a
neonatal model of CHIKV infection. Interestingly, although infants show increased severity, this
is not due to a lack of a robust immune response. In Chapter 2, we demonstrate that both human
infants and neonatal mice generate a robust type I IFN response during CHIKV infection.
Signaling through the type I IFN receptor is at least partially intact, as we were able to detect
IRF7, Mx1 and ISG15 mRNA induction at the site of infection in neonatal mice. In order to
understand mechanistically how type I IFNs protect neonates from CHIK induced lethality, we
evaluated a role for ISG15.
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A role for ISG15 in viral infection has been previously described. During Influenza B and
Sindbis virus infections, ISG15 mediates protection through conjugation. ISG15-/- mice and mice
that lack the ability to form ISG15 conjugates, UbE1L-/-, phenocopy each other and show
increased viral loads compared to WT mice. During CHIKV infection, we also show that ISG15/-

mice have increased susceptibility to viral induced lethality. We were surprised to find,

however, that UbE1L-/- mice phenocopy WT mice during CHIKV infection. We also found that
ISG15-/- mice did not have increased viral loads compared to WT mice. Instead, we observed an
increase in pro-inflammatory cytokines and chemokines in ISG15-/- mice. Altogether, this data
suggested that the mechanism by which ISG15 protects against CHIKV infection is different
from the antiviral role described for ISG15 during both influenza B and Sindbis virus models.
UbE1L is the only identified E1 for ISG15 and we were unable to detect ISG15 conjugates in
CHIKV infected UbE1L-/- mice. Therefore, we hypothesized that the role of ISG15 during
CHIKV infection is conjugation independent and occurs through the regulation of the host
response to viral infection.
To provide additional support for a role for unconjugated ISG15 during CHIKV
infection, we generated recombinant Chikungunya viruses that expressed wild type or
conjugation deficient ISG15, where the C-terminal LRLRGG motif necessary for conjugation
has been mutated to LRLRAA (CHIK-GG and CHIK-AA, respectively). This strategy was
previously employed during Sindbis virus infection, where a LRLRGG expressing recombinant
Sindbis virus could rescue ISG15-/- from lethality, whereas conjugation deficient ISG15
expressing Sindbis could not (10, 11). Once again we were surprised by our results, as we could
not rescue ISG15-/- mice with the CHIK-GG expressing virus. There several possibilities as to
why we were unable to provide protection, including insufficient levels of ISG15 expression or
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ISG15 may not be stably expressed. Our data may also suggest that ISG15 is not expressed in the
right cell type or the expression of ISG15 is required in an uninfected cell. Although there are
several possibilities as to why our wild type ISG15 recombinant virus was unable to rescue
ISG15-/- mice, we hypothesize that this also hints at a novel mechanism for ISG15.
Taken together, our data indicates that ISG15 functions by a previously unidentified
mechanism to control the host response to CHIKV. Free ISG15, not the conjugated form,
appears to be necessary for protection. We also hypothesize from our recombinant CHIKV
model that ISG15 functions in an uninfected cell. Unlike previous models (10, 12), ISG15 is not
directly antiviral, but instead regulates the host immune response.
Unanchored ISG15 can be found within a cell and can also be detected in the serum of
infected mice. In order to determine how ISG15 protects against CHIKV infection, we decided to
characterize both intra- and extracellular free ISG15. Cytokine activity for extracellular ISG15
has been reported and unanchored polyubiquitin chains regulate signaling within cells (13-18). In
Chapter 3, we identify phosphorylation as a possible post-translational modification for serum
ISG15. We also identify the 30kDa ISG15 serum band as ISG15 bound to hemoglobin subunit
beta 1. The consequences of phosphorylation and the functional role of the 30kDa conjugate are
unknown. We hypothesize that for either form of serum ISG15 to have activity, they must signal
through an unidentified ISG15 cell surface receptor.
To identify non-covalent binding partners for ISG15, we used a recombinant tagged
ISG15 construct for immunoprecipitation studies. Through mass spectrometry, we were able to
identify over 140 potential binding partners for intracellular ISG15. Similar to ISGylation, noncovalent binding partners for ISG15 appear to be involved in multiple cellular pathways,
including innate immunity, stress response, vesicle sorting, cytoskeletal and cell signaling. We
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compared conjugation targets to free ISG15 targets and identified some proteins that did overlap
(STAT1, Annexin) (19, 20). However, for the most part, the proteins that we identified
represented novel targets. We found two proteins that were also identified in a Y2H screen
performed by Nadia Giannakopoulos: PCBP1 (poly(C) binding protein 1) and Clathrin
(unpublished data), which may be promising targets. The hits that we have identified need to be
verified, although we have begun this process by demonstrating that ISG15 can co-ip with
MDA5.
One of the mechanistic clues that we gained from our CHIKV model was the increased
pro-inflammatory cytokine production in ISG15-/- mice. Therefore, we began preliminary
investigations into ISG15s ability to regulate cytokine production. We demonstrate that ISG15
has the ability to regulate cytokine production following TLR stimulation and show that free
ISG15 can regulate IL-6 production in response to pIC. We noted that both pIC and CHIKV can
signal through MDA5, a potential non-covalent partner for ISG15. Whether increased cytokine
production in response to pIC is due to ISG15s participation in the MDA5 pathway remains to be
determined. We found that ISG15s ability to regulate cytokine production is complex, as the
cytokine profile produced was dependent on both the type of stimulation and the type of cell.
Altogether, our most significant finding is that ISG15 regulates CHIKV infection
independent of UbE1L mediated conjugation. This provides a unique opportunity to identify a
mechanism of action for free ISG15. To meet this end, we have characterized both intra- and
extracellular ISG15 and have begun functional studies relative to our mass spec results and our
CHIKV model. It is our hope that our findings will not be specific to CHIKV, but will aid our
overall understanding of ISG15s activity as an important effector of the type I IFN response.

146

Future Directions

Although we and others have taken important steps to characterize ISG15, the mechanism(s) by
which ISG15 protects against viral infection is still largely unknown. Below we discuss future
experiments that may aid in this discovery.

Is there a cell surface receptor for ISG15?
Extracellular ISG15 is found in the serum of virally infected mice and has been reported
to have cytokine like activity. Stimulation with recombinant ISG15 results in NK cell
proliferation, neutrophil recruitment, and dendritic cell maturation (13-15). Importantly, a recent
report identifying ISG15 null mutations in humans has shown that recombinant ISG15 has the
ability to regulate cell mediated IFNγ production in concert with IL-12 (16). How ISG15
mediates these activities is not understood, although we hypothesize that it is dependent on
ISG15s ability to bind to an unidentified cell surface receptor.
Jessea Campbell has initiated preliminary investigations into identifying a receptor for
ISG15. Our main goal is to generate recombinant ISG15, identify cells that can bind ISG15, and
then generate a cDNA expression library to search for a possible receptor. We started by staining
splenocytes from pIC stimulated mice with Fc-tagged mISG15 (Fc empty vector and DIII-Fc as
negative controls). Unfortunately, results using Fc tagged versions of ISG15 were inconclusive.
Innate immune cells, possibly neutrophils or CD8 dendritic cells, stained positive for ISG15,
whereas B and T cells were negative. Primary BMM and BMDCs as well as the macrophage
RAW cell line also bound ISG15-Fc (data not shown). Fc empty vector showed no binding and
DIII Fc binding was lower than ISG15-Fc. Interestingly, pretreatment of RAW cells increased
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the amount of ISG15-Fc binding. We hypothesize that, similar to the ISG15 conjugation cascade,
the ISG15 receptor may be induced. However, when we generated a mutant Fc that could not
bind Fc receptor, ISG15 binding was lost. This data suggests that our initial findings were
dependent on Fc binding, although it is unclear why there remained a difference between nonmutant DIII and ISG15 constructs. As an alternative approach, we have generated BirA tagged
ISG15 for the generation of ISG15 tetramers for use in similar experiments.
We hypothesize that innate hematopoietic cells are likely candidates for expression of an
ISG15 receptor, as ISG15s activity has been reported for these cells in the literature and they
play an important role in the initial response to viral infection when ISG15 is first expressed.
Although we have not determined whether ISG15 mediated protection during CHIKV infection
is dependent on intra- or extracellular ISG15, we propose that resident non-hematopoietic cells
(i.e. muscle fibroblasts) should also be investigated, as Schlite et al has demonstrated that IFN
mediated control of CHIKV infection is dependent on non-hematopoietic cells (8).
Generation of recombinant ISG15- mutant Fc for our intracellular mass spec studies as
well as our cell surface staining provided a potential useful tool for investigating the functional
consequences of extracellular ISG15 stimulation. To investigate a role for extracellular ISG15,
we pre and/or post treated ISG15-/- primary BMM and muscle fibroblasts with recombinant
ISG15 and then stimulated with pIC. Supernatant was collected and assayed for cytokine
production via bioplex. Unfortunately, the conditions used to generate the recombinant protein
included a contaminant that led to non-specific activation of BMM, masking any potential ISG15
activity (data not shown). Interestingly, primary muscle fibroblasts did not have non-specific
activation and we observed that pretreatment of these cells dramatically decreased the amount of
IL-6 produced in response to pIC (Fig. 4.1). These results were dependent on high concentrations
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of ISG15, therefore it is unclear whether our results are physiologically relevant. However, this
data may suggest that (1) primary muscle fibroblasts can respond to extracellular ISG15 and (2)
extracellular ISG15 may negatively regulate IL-6 production.
To verify functional readouts for ISG15, data would be strengthened by having the ability
to block extracellular ISG15 activity. We have attempted to block extracellular ISG15 activity in
WT neonates during CHIKV infection by administering a rabbit anti-ISG15 polyclonal antibody
24hrs prior to infection. Unfortunately, our antibody pretreatment did not impact the survival,
viral loads, or cytokine production in WT mice (Fig 4.2). There are many potential explanations
for why our αISG15 antibody could not protect, such as inability of the antibody to block
activity, insufficient amount to block activity, or maybe blocking was successful, but
extracellular ISG15 is not essential during CHIKV infection. To verify the ability of our ISG15
antibody to block extracellular ISG15 activity, we must first establish a functional readout
(preferably in vitro) for recombinant ISG15 stimulation.
Many additional questions need to be addressed to confirm an activity for extracellular
ISG15. We do not know how much ISG15 is released following IFN stimulation or viral
infection. We also do not know whether release of ISG15 is an active process or due to release
from dead or dying cells. If ISG15 secretion is active, what cells are responsible for release of
ISG15 during in vivo viral infection? Interestingly, during influenza B chimeric bone marrow
studies, ISG15 was found in the serum of WT > ISG15-/- infected mice but not ISG15-/- > WT
mice by western blot analysis, suggesting that (1) ISG15 release is an active process and (2)
ISG15 may be secreted from hematopoietic cells (data not shown).
In summary, finding an activity for extracellular ISG15 is dependent on further
characterization of serum ISG15 (post translational modifications (Chapter 3), mechanism of
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secretion, physiological levels) as well as identification of an ISG15 receptor. Once these
parameters have been established, functional relevance may be derived by identifying ISG15ISG15 receptor binding interactions and potential downstream signaling consequences.

Confirmation of non-covalent binding partners for intracellular ISG15
We believe that our identification of non-covalent binding partners for intracellular
ISG15 is a promising start to finding mechanisms for both free and conjugated ISG15. We
recognize, however, that many of the proteins that we have identified using mass spectrometry
may not directly bind ISG15. To confirm binding partners for ISG15, we have begun initial
overexpression co-ip studies using a 293 transfection system. If proteins can be verified via
overexpression, similar co-ip studies can be used to establish endogenous interactions.
Additional mutagenesis analysis will allow for identification of domains and/or residues that are
responsible for ISG15 binding, which may aid in future functional studies. Strength and kinetics
of binding may also be evaluated using recombinant proteins and such techniques as Surface
Plasma Resonance (SPR).
We note that we did not identify any transmembrane proteins from our mass spec
analysis. It is possible that the conditions that we used to generate cytosol from BMM did not
allow for isolation of transmembrane proteins. We also note that our mass spec hits are specific
for IFN/pIC stimulated BMM, therefore may not represent additional binding partners in
different cells or in response to other forms of stimulation (TLR4, inflammasome, etc).
Therefore, our results most likely do not represent the full repertoire of ISG15 binding partners
but may be used to direct attention to certain cell signaling pathways.
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We hypothesize that like ubiquitin, non-covalent ISG15 may be recognized by proteins
that contain an unknown “ISG15 binding domain” (ISGBD). This ISGBD may contain sequence
similarities with ubiquitin binding domains (21, 22). We also hypothesize that ISG15 can
compete with ubiquitin for binding to known ubiquitin binding domains. Therefore, we searched
our non-covalent mass spec results (Table 3.1) for conserved protein binding domains.
Interestingly, so far we have only identified three ubiquitin binding domains that unfortunately,
are not shared by any of our other mass spec hits: UBA (p62), VHS (Gga1) and UIM (Usp25).
Blast searches of portions of these ubiquitin binding domains within functional categories did not
reveal a conserved amino acid sequence shared between mass spec hits. These results are
preliminary and may improve by decreasing the stringency of our Blast searches or by
eliminating proteins on our mass spec list that do not bind ISG15. We suggest that mutagenesis
of a known ISG15 interacting partner may be the best approach for identifying an ISG15 binding
domain.

What are the functional consequences for intracellular ISG15s non-covalent interactions?
From our mass spec analysis, we have identified proteins involved in many different
intracellular pathways, including innate immunity, vesicle sorting, protein translation, cell
metabolism and cell signaling pathways. If we are able to confirm ISG15 binding, we will need
to demonstrate the functional consequences of this interaction. In Chapters 3, we have
highlighted MDA5, a known ubiquitin binding protein, as a promising candidate for ISG15
binding activity. Below we briefly examine a few other candidates that may relate to our
observations during CHIKV infection.
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NCF4 (neutrophil cytosolic factor 4), also known as p40phox, is a member of the
NADPH oxidase. The NADPH oxidase is responsible for the generation of reactive oxygen
species (ROS) that play an important role in macrophage activation and inflammation (23).
p40phox is one of six subunits that makes up the NADPH oxidase and is known to regulate
NADPH oxidase activity in vivo (23). To our knowledge, the contribution of ISG15 to ROS
generation has not been evaluated. Our ability to generate primary knockout cells may allow for
the development of an in vitro model to assess whether or not ISG15 can influence ROS
production.
Poly (C) binding protein 1 (PCBP1) was one of the few mass spec hits that was also
identified in Nadia’s Y2H screen. Poly (C) binding proteins represent a family of RNA-binding
proteins with high affinity and sequence specific interaction with poly(C) (24). PCBPs are
involved in multiple cellular processes and have been shown to regulate mRNA stability,
transcription and translation. Importantly, PCBP1 and PCBP2 have been shown to mediate the
degradation of MAVs through the recruitment of the E3 ubiquitin ligase AIP4 (25, 26). To assess
a role for PCBP1, we may evaluate ISG15s ability to regulate MAVs degradation or MAVs
downstream signaling.
We have also identified several proteins involved in vesicle sorting, including Sorting
Nexins 1 and 2 (Snx1/2), general vesicular transport factor p115 (Uso1), and clathrin heavy
chain 1. The mechanism by which ISG15 is secreted is unknown, therefore we hypothesize that
ISG15s ability to interact with members of vesicular transport may reveal how ISG15 is released.
Knockdown of these sorting proteins may be used to evaluate the importance of these proteins in
ISG15 secretion. We recognize that vesicular sorting proteins play additional roles besides
protein secretion, including membrane remodeling, cell surface receptor recycling and retrograde
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transport from endosomes to the Trans Golgi network (TGN) (27, 28). A potential role for ISG15
in these pathways is unclear.
Another protein that we have identified, p62, also has the capability to bind to both mono
and polyubiquitin. As we have generated preliminary data examining a role for ISG15 in
autophagy and apoptosis, we will discuss these pathways in more detail in the following section.

A quick look at ISG15 and Autophagy/Apoptosis (includes excerpt from Joubert et al
2012).
Past research has shown that both apoptosis and autophagy are induced during Sindbis
virus infection and manipulation of either of these cellular pathways can alter Sindbis disease
progression (29-31). Our collaborators at the Pasteur Institute demonstrate that autophagy is
induced during CHIKV infection and acts in part by limiting apoptosis induction (32). We also
demonstrate that autophagy is necessary for in vivo protection against CHIKV induced lethality.
To analyze the potential role of autophagy in CHIKV pathogenesis we used Atg16L
hypomorphic mice (Atg16LHM) in which Atg16L1 gene has been modified by gene trap
mutagenesis. These mice display hypomorphic expression of Atg16L protein and reduced
autophagy (not depicted; (33)). 9-d-old WT and Atg16LHM mice were infected with CHIKV
and followed for lethality (Fig. 4.3A). Although only 60% of WT mice succumbed to CHIKV,
we observed an increase in lethality in Atg16LHM mice. These data indicate that autophagy has
a pro-survival function during CHIKV infection and limits disease pathogenesis. To understand
how autophagy enhances survival, we analyzed viral load in infected tissues in WT and
Atg16LHM mice (Fig. 4.3B). Viral load in skin muscle and serum, important targets of CHIKV
infection, were similar in WT and Atg16LHM mice, suggesting that autophagy did not
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significantly affect in vivo viral infection. Similar results were obtained by analyzing the viral
load in lung, liver, brain, and spleen (unpublished data). Interestingly, the one observed
difference concerned a delayed clearance of CHIKV in the muscle at day 9 after infection.
Joubert et al go on to show that CHIKV Atg16LHM mice display increased levels of caspase 3
activation compared to WT mice despite similar viral loads (data not shown)(32). Our data
indicates that autophagy limits apoptotic induction of CHIKV infected tissues and delays
lethality of mice.
The ability of ISG15 to regulate autophagy and/or apoptosis is unknown, although we
hypothesize that if ISG15 can regulate autophagy/apoptosis, then increased lethality observed in
ISG15-/- mice during CHIKV infection may result from altered regulation of these two pathways.
Analysis of LC3 and p62 conversion following autophagy induction in vitro did not reveal a role
for ISG15 (Fig. 4.4). WT, UbE1L-/- and ISG15-/- MEFs and BMM were treated with EBSS
(serum starvation) or Rapamycin/Chloroquine to induce autophagy (33, 34), with or without
IFNβ pretreatment. Autophagy induction was assessed by examining LC3-II and p62
accumulation in cell lysates 1-9hrs post stimulation via western blot analysis. Baseline levels of
LC3-II and p62 were equivalent between untreated WT, UbE1L-/- and ISG15-/- MEFs. IFNβ
pretreatment only slightly increased observed levels of LC3-II and p62 above baseline.
Treatment with rapamycin and chloroquine post IFNβ treatment greatly increased the amount of
LC3-II and p62 above baseline, however there was no difference between the three genotypes
(Fig. 4.4A). BMM behaved similarly to MEFs (Fig. 4.4B). ISG15 expression in IFNβ stimulated
cells was also confirmed by western blot analysis. Under these conditions, we were unable to
describe a role for ISG15 in autophagy. We hypothesize that ISG15 may not regulate overall
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autophagy protein levels, but may impact the delivery of cellular components to the
autophagosome.
Although a role for ISG15 in apoptosis/autophagy has not been described, ubiquitin is
known to play an important role in both of these pathways. Both mono-ubiquitin and
polyubiquitin chains are important molecular tags for targeting intracellular protein aggregates,
organelles as well as intracellular pathogens for autophagy (35). Ubiquitinated targets are
recognized by autophagy adaptor proteins, primarily p62 and NBR1, which deliver their
ubiquitinated targets to the autophagosome. These autophagy adaptor proteins have been termed
SLRs (sequestosome 1/p62-like receptors) and represent a newly recognized class of pattern
recognition receptors that link autophagy to inflammation and other innate immune pathways
(35). From our mass spec analysis, we have identified p62 as a potential binding partner for
ISG15 (Chapter 3). Therefore, we hypothesize that, similar to ubiquitin, ISGylated proteins can
be recognized by p62 and somehow influence the autophagy pathway. Alternatively, free ISG15
may bind to p62 and inhibit its ability of p62 to bind ubiquitinated cargo. The consequences of
ISG15s binding to p62 remains to be investigated, but represents an exciting opportunity for
identifying a novel function for ISG15. Through mass spec, we have also identified the p62
interacting protein Keap1 (36, 37), which may also warrant future study.
Ubiquitin has also been shown to play a role in apoptosis, although its role is primarily
dependent on ubiquitylation of target proteins for the proteasome (38). We have also begun
preliminary investigations into ISG15 and apoptosis. No difference in cell viability have been
observed under normal growth conditions for WT, UbE1L-/- and ISG15-/- primary cells (BMM,
BMDC, MEFs, muscle fibroblasts) in vitro. Altering the conditions of in vitro cell growth, by
treatment with IFNβ, pIC or viral infection has also not generated a difference in cell viability,
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although these results have not been closely quantitated or documented. To assess a role for
ISG15 in apoptosis during CHIKV infection, we stained CHIKV infected skin and muscle tissue
from WT, UbE1L-/-, and ISG15-/- neonates with anti-caspase 3 antibody ((Fig. 4.5), staining and
analysis done with the help of Pierre-Emmanuel Joubert). Strikingly, ISG15-/- show increased
levels of caspase 3 staining during CHIKV infection compared to WT and UbE1L-/- mice. We
have previously demonstrated that WT, UbE1L-/- and ISG15-/- mice do not display differences in
skin/muscle viral titers. This suggests that the increase in apoptosis is not due to increased viral
burden in ISG15-/- mice, however this was not directly shown for the caspase3 samples as antiCHIK staining was unsuccessful. Future studies are necessary to establish a role for ISG15 in
apoptosis.

Alphaviruses and ISG15: To conjugate or not to conjugate?
Sindbis virus (SINV) is an alphavirus that is closely related to CHIKV. Like CHIKV,
SINV is an Old World alphavirus that is arthogenic, although neuroadapted strains of SINV have
been described (39). As the role of ISG15 during SINV infection is conjugation dependent (11),
we were surprised when we discovered that ISG15s role during CHIKV infection was not
mediated by UbE1L. This UbE1L independent mechanism of ISG15 was not specific to CHIKV,
as we demonstrated a similar phenotype for additional alphaviruses: RRV and BFV. We do not
understand why ISG15 mediated restriction of some viruses is conjugation dependent while for
others, it appears to be conjugation independent. We hypothesize that viral determinants may
dictate how ISG15 mediates its protective effects. The similarities between SINV and CHIKV
may provide a unique opportunity to identify which viral proteins influence ISG15 restriction, if
this is indeed the case. The generation of chimeric viruses is a common vaccine strategy, and has
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been demonstrated with CHIKV using TC-83 and Sindbis virus backbones (40). Therefore, we
propose domain swap studies between SINV and CHIKV to determine if ISG15s conjugation
restriction can be tied to an individual or set of viral proteins.

What is the role for ISG15 in cytokine production? Does ISG15 regulate cytokine
production in response to other stimuli?
Type I IFNs impact the function of both innate and adaptive immunity. IFN production
leads to activation of DCs and NK cells and also promotes the survival and effector function of B
and T cells (9). It is thought that one of the mechanisms by which IFN alters an immune
response is through the regulation of cytokine production. Indeed, IFNs anti-inflammatory
properties have been used therapeutically for autoimmune or inflammatory disorders, including
multiple sclerosis (MS) (41). Recent research suggests that type I IFN inhibits IL-1β production
and inflammasome activation (42). Although IFN has been suggested to regulate cytokine
production, the mechanism of action is still largely unknown. Due to our CHIKV phenotype, we
hypothesized that ISG15 may be a downstream effector of IFN mediated cytokine regulation.
ISG15-/- mice during CHIKV infection display elevated proinflammatory cytokine levels
compared to UbE1L-/- and WT mice. The levels of TNF observed were similar to that observed
in some adult models of LPS induced septic shock (43, 44) as well as neonatal Sindbis virus
infections (45), where mice are thought to die from a cytokine storm. Necropsy analysis revealed
that ISG15-/- mice had more severe blood vessel and airway injury than WT and UbE1L-/- mice.
ISG15-/- mice also had altered blood chemistry, which may indicate multiple organ dysfunction,
another potential readout for septic shock (Fig S2.5). We hypothesize that the cytokine increase
in vivo may contribute to the increased lethality observed in ISG15-/- mice during CHIKV
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infection and suggest that ISG15s ability to regulate cytokine production is biologically
significant.
As ISG15 appears to impact cytokine production during CHIKV infection, we
investigated cytokine production in ISG15-/- in response to other stimuli. Our lab has previously
shown that the role of ISG15 during influenza B virus infection is conjugation dependent.
ISG15s action is also directly antiviral, as UbE1L-/- and ISG15-/- mice show elevated influenza B
titers compared to WT mice (Fig 4.6A)(12). Interestingly, although conjugation appears to be
essential for protection against influenza B, analysis of cytokines produced indicates a
mechanism of action for free ISG15 during influenza B infection. UbE1L-/- and ISG15-/- mice
have equivalent viral loads during influenza B infection, however, as with CHIKV, ISG15-/- mice
display a marked increase in pro-inflammatory cytokine production (Fig 4.6B). We suggest that
although this cytokine increase does not appear to contribute to the lethality of ISG15-/- mice, the
mechanism of free ISG15 mediated cytokine regulation is still conserved in this influenza B
model. We note that one of the key differences between our influenza B and CHIKV models is
the age of the mice: CHIKV is neonates and influenza B is adults. We speculate that adult mice
are more resistant to cytokine increases, therefore influenza B infected ISG15-/- mice do not
show an increase in lethality compared to UbE1L-/- mice. Indeed, our CHIKV model is also age
dependent, as older ISG15-/- mice are considerably more resistant to CHIK induced lethality
compared to our 9day old model.
In Chapter 3, we demonstrate that ISG15 can regulate cytokine production in response to
pIC stimulation. Interestingly, unlike pIC stimulation or CHIKV infection, LPS treatment leads
to a different pattern of cytokine production (Table 3.2). Following LPS treatment, ISG15-/- mice
and cells show a decrease in IL-6 production. In addition to pIC and LPS, we also tried
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inflammasome activation to evaluate IL-1β production. Although preliminary, our data might
suggest that inflammasome mediated IL-1β production is regulated by ISG15 conjugation.
Altogether, regulation of cytokine production by ISG15 is complex and appears to be dependent
on the type of PRR stimulation.

Bridging Free and Conjugated ISG15: The Molecular Tag Hypothesis.
Although the focus of this thesis has been on free ISG15, we hypothesize that the noncovalent binding properties of free ISG15 may be necessary for the function(s) of conjugated
ISG15. From western blot analysis, we normally observe that only a small percentage of a target
proteins become ISGylated. One of the underlying questions in the field of ISG15 is if only a
small percentage of protein gets modified, how can this have a functional consequence? A theory
has been proposed by (46) based on their observation that the primary E3 for ISG15, Herc5,
associates with ribosomes. They hypothesize that ISG15 non-discriminately labels newly
translated proteins and modification of host proteins is “collateral damage.” Viral proteins are
proposed to be the actual targets of ISGylation and modification of structural proteins inhibits the
ability of a virus to form a mature virion due to steric hindrance, thus inhibiting viral replication.
This would require that only a fraction of viral proteins gets modified, consistent with most
observations.
We wish to extend this theory and propose that ISG15 tags viral proteins for
identification by host proteins. During viral assembly, we hypothesize that ISGylated viral
proteins are recruited to the viral replication complex. Host proteins can then bind and recognize
ISGylated proteins via non-covalent interactions or a hypothetical ISG15 binding domain. This
allows for recruitment of host proteins to the viral replication complex and requires that only a
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small number of viral proteins become modified. For example, we hypothesize that p62 (one of
our mass spec hits) recognizes and binds to ISGylated proteins and targets them for destruction.
P62 is recruited to the viral replication complex, allowing for autophagosome formation around
the viral replicon for targeted destruction. We hypothesize that other host proteins may also be
recruited via a similar mechanism. Another similar theory is that mature virions may be
ISGylated, allowing for recognition by the unidentified ISG15 receptor and
internalization/destruction of the released virus. Although we hypothesize that the “collateral
damage” theory may be valid, we also recognize the potential of ISG15 to serve as an adaptor
between host proteins. Therefore, ISG15 regulation of viral replication may be dependent on (1)
ISG15 conjugation and (2) recognition of ISGylated proteins via ISG15 binding proteins. Future
studies are required to establish a relationship between free and conjugated ISG15.
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Figure 4.1. Pretreating ISG15-/- muscle fibroblasts with recombinant ISG15 results in
decreased IL-6 production. ISG15-/- primary muscle fibroblasts were pretreated with 1-5
ug/mL recombinant ISG15 -mutant Fc or DIII –mutant Fc protein. 24hrs after ISG15
pretreatment, cells were stimulated with 10ug pIC along with (prepost) or without (pre) 1-5ug
ISG15. Cell supernatants were harvested 18hrs post treatment and IL-6 was measured via
Bioplex. Representative of two different experiments (N=2).

161

Figure 4.1
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Figure 4.2. Pretreatment of WT mice with a polyclonal anti-ISG15 antibody did not impact
survival, viral titers or cytokine production during CHIKV infection. (A) Nine day old WT
mice were pretreated with 30uL of anti-ISG15 rabbit polyclonal sera (1552) 24hrs before
infection with 105 PFU CHIKV s.c. Survival was followed for 21 days and compared to
untreated WT mice. (B and C) In a separate experiment, WT mice were pretreated with antiISG15 or a non-specific antibody (1781) 24hrs before CHIKV infection. Skin/muscle from the
site of infection as well as serum was collected on days 1 and 2 post infection. Viral titers were
determined by plaque assay and serum cytokine levels were measured via bioplex.
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Figure 4.3. Autophagy limits apoptotic induction in CHIKV infected tissues and delays
lethality of mice (Joubert et al 2012). (A&B) WT (n = 43) and Atg16LHM mice (n = 34) were
infected at 9 d of age with 4 × 105 PFU CHIKV subcutaneously. (A) Mice were monitored for
lethality for 21 d with data displayed as Kaplan-Meier curves. (B) Skin, muscle, and serum were
collected after days 1, 2, 5, and 9 of infection, homogenized, and viral titers were determined by
standard plaque assay. Median values for WT (black bars) or Atg16LHM (blue bars) mice are
depicted.
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Figure 4.3
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Figure 4.4. ISG15 does not appear to regulate total p62 and LC3-II levels following
autophagy induction (preliminary data). (A) WT, UbE1L-/- and ISG15-/- MEFs were pretreated
with IFNβ and then stimulated with rapamycin and chloroquine (RC). LC3-II, p62, and ISG15
expression 8hrs post RC stimulation were identified by western blot analysis. (B) Activated WT,
UbE1L-/- and ISG15-/- primary BMM were treated with EBSS or RC. LC3-II and ISG15
expression 9hrs post autophagy induction were identified by western blot analysis (p62 was not
detected). Similar results were obtained for earlier timepoints (2-6hrs) for both BMM and MEFs.
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Figure 4.4
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Figure 4.5 CHIKV infected ISG15-/- mice may have elevated levels of apoptosis at the site of
infection compared to WT and UbE1L-/- mice (preliminary data in collaboration with
Pierre-Emmanuel Joubert). Nine day old WT, UbE1L-/- and ISG15-/- mice were infected at with
4 × 105 PFU CHIKV s.c. Skin/muscle from the site of infection was collected on day 2 p.i.
Tissue was fixed in PFA, frozen in OCT blocks, and stained for cleaved capsase-3. Each bar
represents an individual mouse. Number of caspase 3 positive cells was counted from three
separate sections for each mouse.

169

Figure 4.5
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Figure 4.6. Influenza B infected ISG15-/- mice have elevated cytokine and chemokine levels
compared to UbE1L-/- mice despite similar viral loads (Dr. Deborah Lenschow). WT,
UbE1L-/- and ISG15-/- adult mice were infected with influenza B virus. (A) Lung viral titers
were determined on days 3 and 6 post infection via plaque assay. (B and C) Serum cytokine (B)
and chemokine (C) levels were assessed by bioplex on day 6 post infection.
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